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Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine disorder 
among women in the United States.  Women with PCOS experience acne, excessive hair, 
weight gain and irregular periods.  Unfortunately, these women also have cardiovascular 
disease (CVD) risk factors including obesity, inflammation and type 2 diabetes.  It is challenging 
to determine when and if atherosclerosis is accelerated in women with PCOS compared to 
controls as many studies investigate subclinical atherosclerosis in young women and are limited 
by small sample sizes.  The purpose of this dissertation is to investigate markers for subclinical 
atherosclerosis in women with PCOS and non-PCOS controls. 
The meta-analysis on carotid intima-media thickness (CIMT) showed that women with 
PCOS have greater CIMT compared to controls.  The summary estimates of the difference are 
comparable to a seven year progression in CIMT.  This analysis also revealed CIMT estimates 
were more constant across studies with higher quality assessments of CIMT.   
The investigation of serum complement protein C3 (C3) suggested C3 may be an 
inflammatory risk marker for CVD in women with PCOS and controls.  C3 was associated with 
traditional CVD risk factors in women with PCOS and c ontrols, and was associated with 
coronary artery calcium (CAC) after adjusting for case control status, age, and either insulin or 
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BMI.  In the fully adjusted model with African American race, C3 was significantly associated 
with the presence of CAC. 
The trajectory analysis of flow-mediated dilation in women with PCOS and c ontrols 
identified three patterns of change in lumen diameter that were labeled as non-dilators, dilators 
and enhanced dilators.  Baseline lumen diameter, insulin and HDLc were associated with group 
membership, and an interactive effect between PCOS status and total cholesterol on group 
membership was detected.     
The findings from this dissertation clarify the mechanisms of subclinical atherosclerosis 
in women with PCOS and controls.  This is of public health importance because many women 
with PCOS may not realize they are at risk for CVD.  It is critical to evaluate factors that put 
these women at an increased risk of CVD so researchers can monitor risk factors and develop 
interventions to prevent atherosclerosis in this high risk population.  
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1.0  DISSERTATION INTRODUCTION AND OBJECTIVES 
Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine disorder 
among women in the United States.  Women with PCOS experience acne, excessive hair, 
weight gain and irregular periods.  Unfortunately, these women also have cardiovascular 
disease (CVD) risk factors including insulin resistance, abdominal obesity, inflammation and 
type 2 diabetes.  These risk factors and metabolic disturbances may accelerate functional and 
structural impairments of the vascular system in women with PCOS.  The aim of this 
dissertation is to investigate markers for subclinical atherosclerosis in women with PCOS and 
controls.  Three markers of subclinical atherosclerosis were evaluated in the papers described 
below: 
1. Many excellent reviews have discussed the association of PCOS with CVD risk factors 
and the risk of CVD, but a systematic review has yet to be conducted of the evidence of 
subclinical atherosclerosis measured by carotid intima-media thickness (CIMT) in 
women with PCOS.  The aim of the first paper was to perform a systematic review and 
meta-analysis of the conflicting body of literature on CIMT in women with PCOS 
compared to non-PCOS controls.  The results would help to summarize and interpret the 
literature on CIMT in women with PCOS and controls and identify sources of variability 
between studies.   
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2. Recent studies suggest that PCOS is a low-grade inflammatory state, which is 
concerning since atherosclerosis is classified as a vascular inflammatory disease.  There 
has not been an investigation of the association between complement protein C3 (C3), a 
novel inflammatory marker, and subclinical cardiovascular disease in women with PCOS 
and controls.  The goal of paper two was to determine whether circulating serum C3 
levels were higher in women with PCOS compared to non-PCOS controls, and whether 
C3 levels were associated with traditional CVD risk factors and CAC in women with 
PCOS and controls.   
 
3. Flow-mediated dilation (FMD) is a widely used measure of subclinical atherosclerosis, 
but has a lot of variability that makes it hard to interpret the results from the endothelial 
function assessment.  Studies of FMD in women with PCOS compared to controls are 
inconsistent, and could be explained by the variability of the endothelial function test and 
studies having low sample sizes.  The aim of paper three was to use trajectory analysis 
to identify patterns of change in lumen diameter, and evaluate the association between 
PCOS status and other covariates with group trajectories in women with PCOS and 
controls.  This method may reduce the variability in analyzing FMD and could provide a 
new way to understand factors involved in the endothelial response after reactive 
hyperemia.  
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2.0  GENERAL INTRODUCTION 
2.1 DEFINITION AND CAUSES OF POLYCYSTIC OVARY SYNDROME (PCOS) 
Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine disorder 
affecting 6-10% of women in the United States.1,2  The main features of PCOS include excess 
androgens, insulin resistance and obesity.  Women with PCOS experience acne, excessive hair 
(hirsutism), weight gain and irregular periods (less than 8 per year).  However, not all of these 
characteristics are present in a w oman with PCOS, which makes it a difficult syndrome to 
diagnose.   
The two main diagnostic criteria for PCOS have been specified by the National Institutes 
of Health (NIH)3 and the European Society of Human Reproduction and Embryology/American 
Society of Reproductive Medicine (ESHRE/ASRM).4  The NIH has the strictest criteria, defining 
PCOS as 1) androgen excess: clinical (hirsutism, male pattern baldness, acne) and/or 
biochemical (elevated levels of total or free testosterone); 2) ovarian dysfunction: oligoovulation 
(menstrual cycle length >35 days) or polycystic ovaries; and 3)  exclusion of known disorders 
with similar features such as Cushing’s syndrome, hyperprolactinemia, congenital adrenal 
hyperplasia, thyroid dysfunction, neoplastic androgen-secreting tumors or drug-induced 
androgen excess.  The ESHRE/ASRM Rotterdam criterion defines PCOS as two of the three 
following features: 1) oligo/anovulation, 2) clinical/biochemical hyperandrogenism and 3) 
polycystic ovaries by ultrasound after excluding known disorders with similar features.   
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The Rotterdam criteria is controversial because it defines a broader patient population.5  
The Rotterdam adds two more PCOS phenotypes: irregular menses with polycystic ovaries and 
androgen excess with polycystic ovaries.  Depending on how strict a definition, the prevalence 
of PCOS can range from 3% to 22%.6  The heterogeneity in PCOS would likely lower the ability 
of studies to detect associations with PCOS in epidemiological studies.   
To add t o the complexity, not a s ingle factor explains the pathophysiology of PCOS.7  
PCOS was thought to be an autosomal dominant trait because PCOS aggregates in families.8,9  
Legro et al. showed among 155 sisters of women with PCOS, about 22% had PCOS, 24% had 
hyperandrogenaemia but regular menstrual cycles and 54%  were unaffected.10  However, 
investigations have not shown a clear mode of inheritance suggesting PCOS is a complex trait 
such as CVD and type 2 diabetes.5,9,11,12  Studies have evaluated genes involved in hormone 
and metabolic pathways.  A n excellent review of candidate genes in PCOS was done by  
Diamanti-Kandarakis and Piperi.13  A new hypothesis suggests excess androgen exposure 
during fetal development changes gene expression that causes the features of PCOS.7   
PCOS is likely a c ombination of metabolic, hormonal, genetic and environmental 
factors.14  However, the main abnormality in PCOS is thought to be androgen excess or insulin 
resistance.  Many investigators believe androgen excess in PCOS results from dysregulation of 
the hypothalamic-pituitary-ovarian axis (HPO axis)15 or from a dysfunction in the ovary.16  Balen 
et al. and others believe the source of androgen excess comes from abnormal theca cell activity 
in the ovary.16  Theca cells in women with PCOS over respond to gonadotrophins and over 
express androgen producing factors.17  Theca cells in women with PCOS produce levels of 
androgens 20 times higher than normal cycling women.18 
On the other hand, Giallauria et al. and others believe insulin deregulation is the primary 
factor in PCOS.19  Evidence shows most women with PCOS have some form of insulin 
resistance independent of weight.2  Insulin causes the liver to decrease production of sex 
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hormone binding globulin (SHBG).  SHBG binds to testosterone, thus low SHBG levels cause 
hyperandrogenism.  PCOS has been linked to a genetic defect in insulin signaling that causes a 
lower response to insulin.16  Dunaif et al. suggest the defect is in the signal transduction 
between insulin receptor substrate (IRS)-1 and the phosphatidylinositol 3-kinase (PI 3K) 
involved in glucose transport.12     
2.2 TRADITIONAL CARDIOVASCULAR RISK FACTORS IN PCOS 
Numerous studies have shown women with PCOS have higher BMI, abdominal 
adiposity, insulin, triglycerides, total cholesterol, LDLc, SBP and lower HDLc levels when 
compared to controls.20,21  Moreover, several investigators have shown women with PCOS have 
a higher prevalence of CVD risk factors including higher levels of C-reactive protein (CRP),22 
endothelin-1 (ET-1)22,23 and plasminogen activator inhibitor I (PAI-I).24-26  Women with PCOS are 
also at a higher risk of developing type 2 diabetes than healthy counterparts.27  This is 
concerning as insulin resistance plays a role in inflammation, endothelial dysfunction and 
CVD.28,29     
2.3 SUBCLINICAL CARDIOVASCULAR DISEASE IN WOMEN WITH PCOS 
Long-term follow up studies of CVD events in women with PCOS are limited, but several 
studies show women with PCOS have more subclinical atherosclerosis as measured by carotid 
artery intima-media thickness (CIMT)24,25,30-35 and coronary artery calcium (CAC)36-39  compared 
to controls.  Also, studies report women with PCOS have impaired endothelial function, an 
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indicator of early vascular injury, measured by flow-mediated dilation (FMD).22,40-42  This 
epidemiological evidence suggests women with PCOS have adverse structural and functional 
vasculature changes compared to normal menstruating women.    
The following sections will review the current literature of studies evaluating the 
difference in FMD, CIMT and CAC between women with PCOS and non-PCOS controls.  It is 
important to note that most of the studies were cross-sectional case-control studies.   
2.3.1 Endothelial Function: Flow-Mediated Dilation (FMD) 
Endothelial dysfunction indicates early vascular injury and is a functional measure of 
subclinical atherosclerosis.24,43  The endothelium is important for vasodilation, for muscle cell 
growth, limiting adhesion of inflammatory cells and i nhibiting platelet aggregation.28,44-47  The 
endothelium relies on the balance of nitric oxide (NO) and reactive oxygen species (ROS) to 
maintain vasculature tone.48  Epithelial cells overcome sheer stress by releasing NO to relax 
smooth muscle cells thereby increasing the lumen diameter.23,49   
Endothelial function and c an be m easured by brachial flow-mediated dilation (FMD).  
FMD measures changes in brachial artery diameter in response to increased flow after transient 
ischemia (sheer stress).50  A low FMD in response to an  increased blood flow indicates 
endothelial dysfunction.  The most commonly used method to measure FMD involves a 
sonographer that places a tourniquet on the participants forearm and uses B-mode ultrasound 
to measure the baseline advential diameter of the brachial artery.  The sonographer inflates the 
tourniquet 50 mmHg above the participant’s SBP for 4 minutes.  The sonographer deflates the 
tourniquet and measures brachial advential diameter for 2 minutes after deflation.  FMD is 
expressed as a percentage and is calculated by: [(maximum diameter after deflation-baseline 
diameter)/baseline diameter] x 100.   
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Endothelial dysfunction has been s hown in animal models of atherogenesis51 and in 
individuals with atherosclerosis.50,52  Previous studies estimate FMD is around 5% to 15% in 
most individuals, but lower or missing in individuals with cardiovascular disease.49  The 
Cardiovascular Health Study showed the mean FMD was lower among 743  participants with 
clinical CVD (2.93%) compared to 1441 par ticipants without CVD (3.13%; p=0.025) after 
adjusting for important CVD risk factors.53  Endothelial dysfunction is associated with age, 
BMI,54 hypertension,55,56 inflammation29,57 and metabolic factors seen in PCOS such as 
dyslipidemia and insulin resistance.43,58,59   
In addition to these CVD risk factors, potential confounders that affect endothelial 
function include race,60 menstrual cycle,61 estrogens and menopausal status,62,63 exercise,44 
alcohol,64 tea,65 cocoa,66 smoking,67 stress,68 and psychosocial factors including Bortner Type A 
behavior, Spielberger trait anger and Beck depression scores.69  Endothelial function may vary 
by the time of day, but this has not been c onsistently shown.48,70  Medications such as ACE 
inhibitors, statins, antioxidants, insulin sensitizers and L -arginine improve endothelial 
function.44,71  HDLc, adiponectin, vitamin B and folic acid are also positively related to 
endothelial function.26, 43,59    
Studies of FMD in women with PCOS compared to controls are inconsistent (see 
Appendix A).  M ost studies enroll premenopausal women and hav e sample sizes.  T he four 
largest studies, with more than 50 cases, show women with PCOS have statistically lower FMD 
compared to controls.22,33,42,72  Cascella et al. studied 200 women with PCOS (Rotterdam) and 
100 age- and BMI-matched controls with a mean age of 24 years and a mean BMI 29 kg/m2.22  
The women with PCOS had a mean FMD of 13.7% versus 17.8% among controls (p<0.001).  
Investigators consecutively enrolled patients with PCOS through the Department of Molecular 
and Clinical Endocrinology and Oncology in Naples, Italy, and enrolled healthy controls.  
However, they did not specify who the controls were or how they were identified.   
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Similarly, Carmina et al. showed FMD was 15.0% among 50 women with PCOS (NIH) 
versus 18.2% among 50 age- and weight-matched controls (p<0.05).33  Carmina et al. did not 
specify how the women with PCOS and controls were enrolled.  The two other studies showed a 
lower FMD among 62 cases (Rotterdam) and 17 controls42 and among 100 cases (NIH) and 20 
controls.73  However, these studies are limited because they only measured the post-deflation 
maximum diameter at one minute. 
Studies showing no differences in FMD between cases and controls are limited by small 
sample sizes ranging from 10 to 40 cases.74-80  Soares et al. enrolled 40 women with PCOS 
(Rotterdam) immediately after diagnosis at the University of Sao Paulo Hospital, Brazil and 50 
controls from a basic health unit (mean age 24.5 years and mean BMI 23 k g/m2).80  They 
showed FMD was 8.1% among cases and 8.4% among controls (p=0.80).  However, they only 
measured the post-deflation maximum diameter at one minute.  In a similar population, Arikan 
et al. enrolled 39 w omen newly diagnosed with PCOS (Rotterdam) at the Endocrinology 
Department of Medical School of Dicle University, Turkey and 30 ag e- and BMI-matched 
controls from an outpatient clinic.77  The mean FMD among cases was 24.9% compared to 
22.4% among controls (p>0.05).  However, these results are questionable because the mean 
FMDs are surprisingly high.   
The Cardiovascular Health and R isk Measurement (CHARM) study is the only 
investigation of FMD in middle aged women, some postmenopausal, with PCOS and controls.  
Talbott et al. showed no difference in FMD between cases and controls in a subsample of 211 
women from CHARM II from 1997 to 1999.  The mean FMD was 7.33% in 95 women with 
PCOS (NIH) compared to 7.15% in 116 cases.81  However, the women were over 30 years old, 
with a m ean age of 43, and m enopausal status or hormone use was not reported in this 
analysis. 
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The limitations of these studies of FMD and PCOS include low statistical power, the 
study design and m ethodology of FMD.  T he broad Rotterdam criteria would lower a studies 
power to see an effect of PCOS.  Four of the seven studies that did not detect a difference in 
FMD between cases and controls used the Rotterdam criteria.  In addition, most studies had 
inadequate power to detect a difference in FMD between cases and controls due to very low 
sample sizes.  
Some of these case-control studies failed to select a representative control group.  
Studies enrolled patient or community controls,73,76,80-82 doctors, medical students and nurses as 
controls.23,40,41,77,83,84  These controls could be healthier than an average woman, thus 
overestimate the difference in FMD between cases and controls.  Studies that recruited “healthy 
controls” may have potential biases such as self-selection bias and the healthy worker effect.  
These studies did not specify how the controls were recruited or where they came 
from.22,42,75,78,79,85-87  Also, studies did not report the response rate for recruitment that could be a 
source of selection bias.  
These studies compared the mean FMD between cases and controls and did not use 
regression analyses to determine if PCOS is related to FMD independent of the potential 
confounding of important CVD risk factors.  Some investigators did not adjust for differences in 
BMI82 or age.41,75,88  Other important factors related to FMD were not addressed including 
hormone use41,75-77,82,86, smoking 22,78,84,86,88 and differences in baseline lumen diameter.  Some 
studies did not report the baseline lumen diameter.22,41,73,75,76,79 
  Since there is not a standardized protocol of FMD, it is not surprising the methodology 
of FMD varied across studies.  However, there were some differences that limit the ability to 
compare results across studies.  The occlusion time in these studies ranged from three to five 
minutes.  Studies with longer occlusion time may have higher FMD because the longer duration 
of occlusion is associated with a higher FMD.89  Another issue is when investigators measure 
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the post-deflation diameter.  S ome studies measured the maximum post-deflation diameter 
continuously, whereas others measured the diameter at 20 second or 30 second intervals, or 
measured one pos t-deflation diameter at one minute.30,42,59,79,80  The true maximum diameter 
may not be measured in these studies as fewer time points are used.  Alexandraki et al.84 did 
not describe the methods and Lowenstein et al.41 used different equipment (Endo-Pat).   
The differences in FMD methodology would lead to misclassification.  H owever, the 
misclassification would occur in cases and controls (non-differential).  Thus, studies would have 
a harder time to detect a difference in FMD between groups.    
2.3.2 Carotid Artery Intima-Media Thickness 
The thickness of the intima-media in the common carotid artery is a structural measure 
of subclinical atherosclerosis.  Carotid intima-media thickness (CIMT) is measured from B-mode 
ultrasound and is a strong predictor of CVD events 90-93 and CVD risk factors. 94,95  The 
Cardiovascular Health Study followed 5,858 participants for an average of 6.2 years, and found 
every one standard deviation increase in CIMT had a relative risk of 1.3 (95% CI 1.23-1.52) for 
myocardial infarction and relative risk of 1.33 (95% CI 1.20-1.47) for stroke after adjusting for 
CVD risk factors.96 91   
The majority of epidemiological studies show women with PCOS have higher CIMT 
values than controls;24,26,31,34,97-105 one study showed this observation only in older women.106  
However, some studies show no difference in CIMT between cases and controls.30,77,80,84,107-111  
Most studies enrolled premenopausal women with the exception of the study by Talbott et al.112 
Cascella et al. conducted the largest study of CIMT in 200 cases (Rotterdam) and 100 
age- and BMI-matched controls with a m ean age of 24 years and mean BMI of 28 kg/m2.101  
They showed the mean CIMT was 0.46 mm among cases and 0.38 mm among controls 
11 
 
(p<0.001).  In a population with a similar age and BMI, Carmina et al. also showed the mean 
CIMT among 95 cases (Androgen Excess Society criteria) was 0.61 mm compared to 0.53 mm 
among 90 controls (p<0.01).26   
However, Erdogan et al. showed no difference in CIMT between 68 cases (Rotterdam) 
and 26 controls with a mean age 25 years and mean BMI 24 kg/m2.109  CIMT was also similar 
between cases and controls in a slightly older and heavier population (mean age 33 years, 
mean BMI 37 kg/m2).  The mean CIMT was 0.55 mm among 100 cases (NIH) compared to 0.54 
mm among 20 controls (p>0.05).30   
In the CHARM study, there was no difference in the age- and BMI-adjusted mean CIMT 
between 125 c ases (NIH) and 142 c ontrols (0.70 versus 0.67 mm, p=0.30, respectfully).112  
However when stratified by age, a significant difference in CIMT was seen between cases and 
controls in women over 45 years old, but not between women 30-44 years old.  Among women 
20-44 years old, 78 c ases had an a ge and B MI-adjusted mean CIMT 0.65 mm compared to 
0.64 mm among 82 controls (p=0.565).  Among women 45 years and over, 47 cases had an 
age- and BMI-adjusted mean CIMT of 0.77 mm compared to 0.71 mm among 60 c ontrols 
(p=0.005).  I n linear regression models, PCOS remained significantly associated with CIMT 
(beta=0.206, p=0.042) after adjusting for age and BMI. 
Similar to the limitations of the studies investigating FMD, the different associations of 
CIMT and P COS in these studies is likely due t o low statistical power, the study design and 
methodology of CIMT.  The broad Rotterdam criteria would lower a s tudies power to see an 
effect of PCOS.  T he sample sizes ranged from 16 t o 200 s o the smaller studies may have 
lacked sufficient power to detect a difference in CIMT between cases and controls.   
A few studies enrolled patients30,80,99,110 and community controls.34,97,112  Some studies 
may have potential biases due to the control group.  Studies enrolled doctors, medical students 
and nurses as controls,31,77,84,98,102,103  and some did not mention where the “healthy controls” 
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came from or how they were recruited.24,26,100,108,109,111,113  Also, the response rate of the 
recruitment was not reported in any study that could lead to a potential selection bias.  
Most studies controlled for important confounders between women with PCOS 
compared to controls.  Only a few studies did not adjust for significant differences in age and 
BMI between cases and controls98,102,111 and some studies failed to assess hormone use.77,97-
100,102,112  The protocol for CIMT varied across studies; however in contrast to FMD, CIMT is 
more reproducible so the variability is less of a concern than with studies assessing FMD.   
2.3.3 Coronary Artery Calcium 
The presence of coronary artery disease, or coronary artery calcium (CAC), is evaluated 
by using electron beam computed tomography (EBCT).  CAC has been shown to indicate the 
extent and s everity of CVD above that of traditional CVD risk factors, C-reactive protein and 
CIMT.114-116  Moreover, CAC predicts CVD events better than the Framingham risk 
score.114,115,117   
Three studies showed the prevalence of CAC, dichotomized as none versus any, was 
higher in premenopausal women with PCOS compared to controls.  Christian et al. enrolled 36 
cases (NIH) and 71 a ge- and BMI-frequently matched community controls.  The mean ages 
were 38.5 for cases and 39.0 for controls and the mean BMI was 31.4 for cases and 31.2 for 
controls.  The prevalence of CAC  was 39% among 36 cases compared to 21% among controls 
(odds ratio 2.37; p=0.05).38  Mean CAC scores were also higher among cases versus controls 
(8.9 versus 1.7; p=0.03, respectfully).  P COS was not independently associated with the 
prevalence of CAC after adjusting for BMI (odds ratio 1.99; p=0.21), or associated with the 
mean CAC score (p=0.26) after adjusting for BMI, waist circumference, fasting glucose, HDLc 
and triglycerides.   
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Shroff et al. enrolled 24 cases (NIH) from the PCOS clinic at the University of Iowa and 
24 age- and BMI-matched controls from annual exam visits at the Gynecology Clinic and b y 
advertisements in the hospital newspaper.  The prevalence of CAC was 33% among cases 
versus 8% among controls (odds ratio 5.5; p<0.03).37  However, they may have a potential 
selection bias for excluding chronic illnesses like asthma, inflammatory bowel disease, or any 
illnesses within a month preceding the study. 
The Cardiovascular Health and R isk Measurement Study (CHARM) is the only 
prospective study that was able to measure CVD risk factors nine years before the CAC 
assessment.39  The prevalence of CAC was 45.9% among 61 women with PCOS (NIH) versus 
30.6% among 85 controls of similar age (p=0.059).  PCOS remained a statistically significant 
predictor of CAC after adjusting for age and B MI (odds ratio 2.31, p=0.049), but not after 
adjusting for triglycerides, insulin or HDLc.  The women were 35 to 62 years old, but 
menopausal status was not assessed in this analysis. 
In a cross-sectional analysis of women 35-60 years old from the 2000-2003 follow-up, 
the prevalence of CAC was 63.1% in 149 cases versus 41.0% in 166 controls (p=0.037) after 
adjusting for age and BMI.36  PCOS status remained statistically significant in a logistic 
regression model of CAC (CAC ≤10 versus >10) after adjusting for age, BMI, HDLc, fasting 
glucose and menopausal status.  In addition to PCOS, fasting glucose (OR 1.04, p=0.009) and 
menopausal status (natural menopause OR 3.7, p=0.008; surgical menopause OR 3.13, 
p=0.037) significantly predicted CAC.  
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2.4 THE CARDIOVASCULAR HEALTH AND RISK MEASUREMENT STUDY (CHARM) 
Two papers in this dissertation were based on the Cardiovascular Health and R isk 
Measurement Study (CHARM) that has been ong oing since 1992 ( Dr. Evelyn Talbott et al.).  
The aim of CHARM I was to evaluate the prevalence of CVD risk factors in women with PCOS 
compared to controls.  Since then, there have been three phases of the CHARM study (Table 
2.1).    
In CHARM I, investigators identified women aged 19-55 years old diagnosed with PCOS 
between 1970 and 1993 through medical records in the Division of Reproductive Endocrinology 
at Magee-Women’s Hospital (Pittsburgh, PA).20,39  Investigators used NIH criteria to define 
PCOS and m atched cases to neighborhood controls by age ±5 years and race using voter’s 
registration tapes and the Cole’s Cross Reference Directory of Households from 1993.3   
From CHARM I, Talbott et at. showed women with PCOS had significantly higher BMI, 
LDLc, insulin, triglycerides, waist hip ratio and lower HDLc than age matched controls.20  
Subsequent reports showed the difference in CVD risk factors between cases and c ontrols 
differed by age group.81,118  When stratified by <45 years old versus ≥45, younger women with 
PCOS had higher LDLc, total cholesterol after adjusting for BMI, hormone use and insulin than 
controls.  There were no differences between cases and controls after 45 years old.  Similar 
results were found using age 40 as the cutoff.118 
  In CHARM II and CHARM III, Talbott et al. evaluated markers of subclinical 
atherosclerosis that included CAC, CIMT and FMD in women with PCOS and cases over 30 
years old.  As described in the literature review above, women with PCOS had greater CIMT81 
and CAC39 compared to controls, but no difference in FMD.   
From CHARM III, Talbott et al. showed 149 women with PCOS had a higher risk of 
developing type 2 diabetes than 166 controls.27  Among all races aged 35-64 years, the relative 
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risk of type 2 diabetes associated with PCOS was 2.38 (p=0.06) after adjusting for age and BMI 
group.  The population attributable risk percent of type 2 diabetes associated with PCOS was 
7.6%, assuming the prevalence of PCOS is 6% in the general population.  Fo r Caucasian 
women aged 40-59, the relative risk of type 2 di abetes associated with PCOS was 3.95 
(p=0.03) adjusted for age and B MI group.  T he population attributable risk percent of type 2 
diabetes associated with PCOS was 15%, assuming the prevalence of PCOS is 6% in the 
general population. 
 Future follow-up of the women in CHARM will allow investigators to evaluate the risk of 
CVD events among women with PCOS and controls.  Future studies will also be able to assess 
the role of menopause and subclinical atherosclerosis in these women.   
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2.5 TABLE FOR CHAPTER TWO 
Table 2.1 Phases of the CHARM study (1992-2006) 
Phase CHARM I 
1992-1995 
CHARM II 
1997-1999 
CHARM III 2002-2006 
Visit 1 
2002-2003 
Visit 2 
2002-2004 
Visit 3 
2003-2006 
Participants N=486 
243 cases and 
243 controls 
N=335  
161 cases and 
174 controls 
N=328 
157 cases and 
171 controls 
N=228 
108 cases and 
120 controls 
N=276  
125 cases and 
151 controls 
Measurements Fasting blood 
draw, medical 
history and 
anthropometric 
measures 
Fasting blood 
draw, medical 
history, 
anthropometric 
measures     
(CT-measured) 
and subclinical 
CVD measures 
(CIMT, FMD)  
Fasting blood 
draw, medical 
history and 
anthropometric 
measures and 
EBCT (CAC)   
Subclinical 
CVD: PWV 
(N=212),  
CIMT (N=225) 
and FMD 
(N=187)   
Fasting blood 
draw and 
repeat EBCT 
(CAC) 
  
 
 
Repeat CIMT 
and FMD 5 yrs 
later CHARM III 
Visit 2 
Repeat EBCT 3 
yrs later CHARM 
III Visit 3 
  
 
*Fasting blood draw included hormone, lipid and metabolic panels as well as selected inflammatory, 
fibrinolytic and coagulation factors; anthropometric measures included BMI, waist-hip-ratio and waist 
circumference.  CT: computed tomography; CIMT: carotid intima-media thickness; FMD: flow-mediated 
dilation; PWV: pulse wave velocity; EBCT: electron beam computed tomography  
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3.0  CAROTID ARTERY INTIMA-MEDIA THICKNESS IN POLYCYSTIC OVARY 
SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS  
3.1 INTRODUCTION 
Polycystic ovary syndrome (PCOS) is a r eproductive endocrine disorder that affects 
approximately 7 million women, about 6-10% of women, in the United States.1,2  Women with 
PCOS experience acne, excessive hair, weight gain and irregular periods.  Unfortunately these 
women also have an i ncrease in  c ardiovascular disease (CVD) risk factors including insulin 
resistance,3 dyslipidemia,4 abdominal obesity,5 type 2 diabetes6 and inflammation.7  These risk 
factors and metabolic disturbances may cause functional and s tructural impairments of the 
vascular system in women with PCOS and have long-term effects on t he process of 
atherosclerosis as these women age.   
The extent to which there is an i ncreased risk of subclinical atherosclerosis and C VD 
events among women with PCOS remains controversial.  Studies of CVD events in women with 
PCOS are limited, but a recent meta-analysis showed women with PCOS had two times the risk 
of coronary heart disease or stroke than controls.32  Some studies have found that women with 
PCOS had greater subclinical atherosclerosis as measured by coronary calcification (CAC),8-11 
carotid artery intima-media thickness (CIMT)12-18 and endothelial dysfunction measured by flow 
mediated dilation (FMD)5,19-21 compared to controls, but not all showed a significant difference.22-
25  Most of these investigations for subclinical atherosclerosis evaluated young women of 
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reproductive age, a time generally early for the detection of atherosclerosis, and were limited by 
small sample sizes.  This provides a challenge to determine when and if atherosclerosis is 
accelerated in women with PCOS compared to controls.   
Many excellent reviews have discussed the association of PCOS with CVD risk factors 
and the risk of CVD,26-31 but a systematic review has yet to be conducted of the evidence of 
subclinical atherosclerosis in women with PCOS.  Thus, the aim of this study was to review the 
literature regarding CVD risk assessment by CIMT in women with PCOS compared to controls.  
CIMT is a non-invasive ultrasound measure of the thickness of the intima-media of the common 
carotid arteries.  It is a w idely used structural marker of subclinical atherosclerosis that is 
associated with CVD risk factors33,34 and CVD events.35-38  This report follows the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.39,40 
3.2 METHODS 
3.2.1 Eligibility Criteria  
Primary articles investigating CIMT among women with PCOS and non P COS controls 
were included if they: (1) were a peer-reviewed primary article, (2) had a study population of 
women with PCOS (diagnostic criteria for PCOS specified by the National Institutes of Health 
(NIH),41 the European Society of Human Reproduction and Embryology/American Society of 
Reproductive Medicine (ESHRE/ASRM),42 and/or the Androgen Excess Society (AES) 
criteria),43 and were compared to non PCOS controls, (3) reported a measure of CIMT 
(unadjusted or adjusted), and (4) were published in the English language.  We excluded studies 
without a control group.   
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3.2.2 Search Strategy and Study Selection 
 Papers assessing CIMT in women with PCOS were identified using Ovid MEDLINE, 
EMBASE and P UBMED.  The primary search was conducted in Ovid MEDLINE through 
November 19, 2010 ( MLM).  T he search terms for Ovid MEDLINE included carotid artery 
diseases, tunica media, carotid artery, common/tunica intima, arteriosclerosis, intima-media 
thickness and polycystic ovary syndrome: physiopathology, pathology, complications, etiology, 
mortality, ultrasonography, epidemiology, prevention and control (Figure 3.1).  The search terms 
for EMBASE were intima-media thickness, ovary polycystic disease limited to humans and 
limited to the publication years to 1980-2010.  A search through PUBMED did not identify any 
new references.  Two independent investigators reviewed reference lists from primary search 
(MLM, EOT). Review papers were assessed to find possible references not identified in the 
Medline and E MBASE journal databases.  B efore finalizing this meta-analysis, a s earch in 
PUBMED identified an additional study published in 2011.   
3.2.3 Data Extraction   
The data from the studies was extracted into a table and re-verified (MLM).  The 
information from each study included: first author, journal, study design, whether the study 
controlled for age and BMI or weight, PCOS diagnostic criteria used, source of the control 
population, number of participants, mean age and BMI of the participants, measure of CIMT 
(both unadjusted and adjusted were extracted if reported), p-value for the difference between 
cases and controls, and the methodology for the CIMT measurement (carotid segments used, 
the calculation of CIMT and reproducibility information).   
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Two investigators met to discuss eligibility of studies to be included in the meta-analysis 
(MLM, EOT).  In any cases of disagreement, a third arbitrator was consulted (RAW). Two of the 
three investigators were required to be in agreement.  After reviewing articles, 26 studies met 
the inclusion criteria and 19 studies were suitable for the meta-analysis (Figure 3.2).  One article 
published in 2011, as mentioned previously, was added t o the meta-analysis.44  For the 
statistical analysis, three studies were excluded that did not report necessary information for the 
meta-analysis,25,45,46 one paper for reporting unusual CIMT values47 and four papers that were 
from the same author or study population.48-51  In instances of duplicate papers from the same 
first author, the most recent study containing the larger sample size was included in this meta-
analysis.   
3.2.4 Assessment of Risk of Bias 
Two investigators independently assessed limitations and pos sible biases within each 
study (MLM, EOT).  This information was used to determine if studies were adequate for the 
meta-analysis and to determine possible sources of heterogeneity.  A priori, it was hypothesized 
that the studies might differ according to the protocol and reproducibility of CIMT and the PCOS 
diagnostic criteria that was used.  Publication bias across studies was assessed using a funnel 
plot and Egger’s test.    
3.2.5 Data Analysis 
The primary outcome of interest was the mean difference in CIMT between women with 
PCOS and non PCOS controls.  T he meta-analysis was performed using a random-effects 
model to compute the mean difference in CIMT and the 95% confidence intervals for each study 
31 
 
and an overall summary estimate.  The mean CIMT, the standard deviation and the sample size 
were available for most of the studies.  Four  studies were included that reported means and 
exact p-values44,52,53 and three studies were included that used an adjusted mean CIMT.13,14,52  
Three studies were ineligible to be included for the meta-analysis because they did not report 
the necessary information.25,45,46  One study was excluded because the reported CIMT was 
unusually low in both women with PCOS and controls.47  One study stratified cases by levels of 
the homeostasis model assessment-insulin resistance (HOMA-IR) but not the control group.54   
In this case, the information from the case group that was most similar to controls was used to 
give a conservative estimate.  The right CIMT results were used for three studies that reported 
the left and right CIMT separately.54-56   
 Forest plots were created with the random effect model to obtain an estimate of the 
overall mean difference in CIMT across the studies.  The random effects model was used to 
incorporate greater variability or heterogeneity between the studies.  The a priori hypothesis 
was that the heterogeneity may be due to differences in PCOS diagnostic criteria, the age and 
BMI of the study populations, the protocol for CIMT and the observer variation of the 
technician(s) performing the ultrasound assessments.  B eyond visual assessment for 
heterogeneity, homogeneity was tested using the chi-square test Cochran’s Q-statistic.  A  p-
value of <0.10 was used to suggest heterogeneity.  The I2 statistic was computed to measure 
the proportion of inconsistency that could not be explained by chance in each of the individual 
studies.57  I2 ranges between 0% and 100% with lower values representing less heterogeneity.  
The recommended guidelines for low, moderate and high I2 values are <25%, 50% and >75%, 
respectfully.57  However, the power to detect bias is under 0.80 with a meta-analysis of less than 
20 studies and including studies with less than 80 participants.58-60  
To examine possible sources of heterogeneity between studies, the meta-analysis was 
conducted by grouping the studies by the quality of the CIMT measurement.  The quality of the 
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studies was determined by evaluating if the study reported reproducibility of CIMT and i f the 
study used an average of the left and right common carotid artery (CCA) for CIMT versus just 
one side.  This criteria was used because the average of measures from the left and right CCA 
would be more stable than the average of one side.61  Finally, to assess possible publication 
bias, a funnel plot was created to assess for symmetry and t he Egger regression test was 
performed to test for asymmetry of the funnel plot.  The Egger test evaluates the association 
between the standardized effect estimate (estimate divided by standard error) and the precision 
(1/standard error) through the use of linear regression for Y-intercept=0.62  All analyses were 
performed using Comprehensive Meta-Analysis software (Borenstein M, Hedges L, Higgins J, 
Rothstein H. Comprehensive Meta-analysis Version 2, Biostat, Englewood NJ (2005)). 
3.3 RESULTS 
3.3.1 Description of Studies 
A total of 56 ar ticles were identified for the review through a database search of Ovid 
MEDLINE and EMBASE after adjusting for duplicates (Figure 3.2).  The investigator screened 
the title and abstracts and excluded 20 articles because they were reviews, did not have a 
control group or did not report a CIMT measurement.  There were 36 full-text studies that met 
the eligibility criteria for this systematic review and meta-analysis.  Of these, 10 s tudies were 
excluded because they were not in English, did not have a control group, or did not report a 
CIMT value.  Eight studies were excluded from the meta-analysis because they had the same 
first author or study population, the necessary statistics were not reported or the CIMT values 
were abnormal compared to the other studies, as previously mentioned.  I n summary, the 
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search identified 27 studies for the systematic review and 18 studies for the meta-analysis.  An 
additional article published in 2011 was identified and subsequently added to the meta-analysis, 
for a total of 19 studies to be included in the meta-analysis. 
The majority of the 27 studies included in the systematic review were cross-sectional 
studies with the exception of one r andomized clinical trial17 (Table 3.1).  T he details of each 
study are shown; however this paper focused on studies that were included in the meta-analysis 
(Table 3.2).  The 19 studies in the meta-analysis involved a total of 1123 women with PCOS 
and 923 non PCOS controls.  The sample sizes ranged from 18 to 200 women with PCOS and 
from 12 to 124 controls.  Women with PCOS were diagnosed using the NIH criteria, the AES 
criteria or the Rotterdam criteria.  The studies enrolled patient,25,45,54,63 community controls,17,48,52 
doctors, medical students and nurses as controls.13,22,53,55,64,65  Some studies did not specify 
where the healthy controls came from or how they were recruited.14,24,44,49-51,66,67   
The studies enrolled women with a mean age range from 22 to 40 years old and a mean 
BMI range from 21 to 30 kg/m2.  The women were premenopausal with the exception of one 
study.52  All but four44,64,65,67 studies matched or adjusted for age and BMI or weight between 
women with PCOS and controls for the CIMT estimate.  C IMT was assessed using B-mode 
ultrasound of the common carotid artery and calculated as a mean of measurements of the far 
wall of the left and right common carotid artery.  One study used the maximum CIMT.44  Most 
studies averaged the right and left CCA together, whereas a few reported them separately.  The 
mean CIMT ranged from 0.41 to 0.75 mm in women with PCOS and from 0.33 to 0.74 mm in 
non PCOS controls. 
Quality control measures for CIMT were reported in nine studies.  The most common 
reported reproducibility statistic was the intra-observer coefficient of variation (CV).  T he CV 
shows the variability between measures where low CV values indicate less variability in the 
measures.  The intra-observer CV for the seven studies were <11%,5,13,14,17,44,66,68  and the inter-
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observer CV for one study was 12%.14  One study reported an intra-class correlation coefficient 
(ICC) of 0.8612 where higher values indicate more measurement variability is due to differences 
between patients rather than other sources of error.  One study reported an intra-observer error 
of  < 0.03 mm.18  The remaining 11 studies did not mention the quality control measures for 
CIMT.23,54-56,65,69  But, five of these studies indicated there was one technician reading the CIMT 
images.22,24,47,53,67   
From this information, the studies were ranked by the quality of the CIMT assessment.  
There were eight studies considered to be of highest quality because they reported a 
reproducibility statistic and used the left and right CCA for CIMT.5,12,14,17,18,44,68  Two studies were 
considered the next highest quality because they reported a r eproducibility statistic and used 
one CCA for CIMT.13,66  Five studies were considered to be of fair quality because they did not 
report a reproducibility statistic and used the left and right CCA for CIMT.22,24,53,65,67  The 
remaining six studies were the lowest quality because they did not report a reproducibility 
statistic and used one CCA for CIMT.23,54-56,69 
3.3.2 Risk of Bias 
The funnel plot of the eight highest quality studies suggested no evidence of publication 
bias because the studies were symmetrical around the mean and the Egger’s regression test 
was not significant at p=0.94 (Figure 3.3).  Publication bias was not assessed among the two 
studies of the next highest quality as this requires more than three studies to run publication 
bias procedures.  The funnel plots of the fair and lower quality studies were also symmetrical 
around the mean (data not shown) and the Egger’s test p-value was 0.48 for the five studies 
without reproducibility and used the right and l eft CCA, and the p-value was 0.61 for the six 
studies without reproducibility and used one CCA.    
35 
 
3.3.3 Mean Difference in CIMT  
The forest plots showed that the mean difference in CIMT between women with PCOS 
and controls varies across the groups of studies (Figures 3.4 to 3.7, Table 3.3).  The forest plot 
of the eight studies of the highest quality suggested cases had a greater CIMT than controls as 
most of the estimated difference in means, except one, were to the right of zero (Figure 3.4).  
The widths of the 95% confidence intervals (CIs) were similar, which indicated the studies had 
similar precision in the estimates.  The summary random effect mean difference in CIMT 
showed that PCOS women had a s ignificantly greater CIMT than controls (0.072, 95% CI 
[0.040, 0.105], p<0.0001).  The Q-statistic for heterogeneity was significant (χ2=36.82, 
p<0.0001, I2=80.99).  However, as noted above, these heterogeneity estimates should be 
interpreted with caution because they are not reliable with a small number of studies and small 
numbers of participants within some studies.   
Like the previous studies, the forest plot of the two studies of the next highest quality 
showed that the estimated difference in means and 95% CIs were similar and were located to 
the right of zero (Figure 3.5).  The summary random effect mean difference in CIMT showed 
that PCOS women had a significantly greater CIMT than controls (0.084, 95% CI [0.042, 0.126], 
p<0.0001).  The Q-statistic for heterogeneity was not significant (χ2 =0.05, p=0.82, I2=0.00).  
This signifies similarities or homogeneity between the studies, but this is based on two studies.  
The forest plot of the five studies of fair quality showed that most of the estimates and 
95% CIs cross zero, except for one study (Figure 3.6).  Two studies had a wide CI compared to 
the rest, which indicated less precision in the estimate.  In contrast to the highest quality studies, 
the estimates of the difference in CIMT across studies did not show a consistent pattern.  The 
summary random effect mean difference in CIMT was not significant between women with 
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PCOS and c ontrols (0.041, 95% CI [-0.038, 0.120], p=0.310) and the Q-statistic for 
heterogeneity was significant (χ2 =30.11, p<0.0001, I2=86.72).   
Similar to the fair quality studies, the forest plot of the six studies of lower quality showed 
that most of the estimates were around zero and the 95% CIs crossed zero, except for one 
study (Figure 3.7).  Similar to the fair quality studies, there was not a consistent pattern in the 
estimated difference in means and C Is across studies.  T he summary random effect mean 
difference in CIMT was not significant between women with PCOS and controls (0.045, 95% CI 
[-0.020, 0.111], p=0.173) and the Q-statistic for heterogeneity was significant (χ2 =43.58, 
p<0.0001, I2=88.53).     
3.4 DISCUSSION 
3.4.1 Summary of Evidence 
Overall, this meta-analysis suggested that women with PCOS have a higher mean CIMT 
compared to non PCOS controls.  The summary estimate of the mean difference in CIMT was 
0.072 mm for women with PCOS compared to controls (95% CI [0.040-0.105], p <0.0001) for 
the studies that reported reproducibility of CIMT and used the left and right CCA for CIMT in the 
meta-analysis.  This was similar to the estimate for studies that reported reproducibility of CIMT 
and used one C CA for CIMT (0.084 mm, 95% CI [0.042, 0.126], p=0.0001).  The summary 
estimate of the difference in CIMT for the two groups of studies that did not report the 
reproducibility of CIMT was higher, but not significantly different, for women with PCOS 
compared to controls.   The average annual change in CIMT for women is estimated to be 
around 0.00970 and 0.015 mm per year,71 thus the summary mean difference corresponds to 
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about a seven year progression in CIMT.  A large magnitude of difference in CIMT was detected 
in this meta-analysis despite including small studies of young women.   
These results should be viewed in light of the significant heterogeneity across studies.  
As previously mentioned, these tests may have had l ow power.  Nonetheless, heterogeneity 
could be due to between study differences in PCOS phenotypes, age, BMI, CVD risk factors 
and technical factors related to assessment of CIMT.  Larger studies with a well-defined PCOS 
population using rigorous methodology may be r equired to draw a more robust conclusion.  
However, the evidence to date suggests women with PCOS are at greater risk of premature 
atherosclerosis that emphasizes the importance of screening and reducing CVD risk factors to 
prevent progression of CVD this high risk subgroup.   
3.4.2 Strengths and Limitations of the Review 
The limits of the search and the inclusion of only studies in the English language may 
have introduced possible publication bias in the meta-analysis.  However only three non-English 
studies were excluded and we did not detect evidence of publication bias from the funnel plots 
or Egger’s test.  Another limitation was the heterogeneity that suggested the populations and 
CIMT measurements were not the same across studies.  The heterogeneity was addressed by 
using the random effects model and grouping the studies according to quality of the CIMT 
measurement.   
CIMT is a r eproducible measure, but has within and bet ween study variability due t o 
random error and error from study participants and t echnicians.  La rger variability of CIMT 
would decrease the reproducibility and require larger sample sizes to maintain adequate power.  
The subgroup analysis showed that the consistency of the estimates across studies increased 
as the quality of the CIMT measurement increased.  The higher quality studies had consistent 
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CIMT estimates across studies and a more robust summary estimate.  This is in contrast to the 
lower quality studies in which the estimates had more variation across studies.  There were a 
few estimates with a wide CI that suggested lower precision in the estimate, and the summary 
estimate was much weaker and not significant at p<0.05.  These observations demonstrate the 
importance of reporting quality control measures and describing the protocol and reproducibility 
of CIMT.  A large portion of the studies did describe quality control measures for the CIMT 
measurement.22-24,47,53-56,65,67,69   
Heterogeneity between studies could also be due to differences in the prevalence of 
CVD risk factors and PCOS phenotypes.  The Rotterdam criterion adds an addi tional less 
severe phenotype to the diagnosis, which could increase heterogeneity and m ay lower the 
power of a study to detect a difference between PCOS and non PCOS participants.  There is 
evidence that the prevalence of CVD risk factors vary by PCOS phenotypes.72  Women with the 
classical definition of PCOS had a hi gher prevalence of one or more CVD risk factors (C-
reactive protein, lipids, homocysteine) than ovulatory women with PCOS.  Women with classical 
PCOS also had m ore abdominal obesity than ovulatory women with PCOS with similar BMI 
(p<0.05).  O n the other hand, nonhyperandrogenic PCOS women, which are included in the 
Rotterdam criteria and not the NIH criteria, had normal androgen levels and lower prevalence of 
insulin resistance and metabolic abnormalities than classical or ovulatory PCOS.   
The meta-analysis is also vulnerable to limitations within each study that include their 
cross-sectional study designs and small sample sizes.  Smaller studies may have lacked 
sufficient power to detect a difference in CIMT between cases and controls as the sample sizes 
of the studies ranged from 18 to 200 women with PCOS and 12 to 142 controls.  Another 
limitation was the potential selection bias within the studies.  The response rate of recruitment 
was not reported in any of the studies, which may lead to potential selection bias.  In addition, 
there were differences in the average age and BMI between women with PCOS and controls in 
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some studies, but this was controlled for in all of the studies except three.64,65,67  An analysis 
without these studies did not change the results.   
The strength of this paper is that the meta-analysis was able to summarize results from 
the conflicting body of literature and increase statistical power by estimating a summary effect.  
Also, grouping studies by the quality of the CIMT measurement identified potential sources of 
heterogeneity and dem onstrated the robustness of the results.  This first meta-analysis to 
investigate CIMT between women with PCOS and controls was able to assess a reliable 
measure of subclinical atherosclerosis using studies limited with small sample size.   
3.4.3 Comparison with Previous Research 
Overall, this meta-analysis indicated women with PCOS had a 0.072 to 0.084 mm higher 
CIMT compared to controls.  This is similar to studies showing women with PCOS are at higher 
risk of subclinical atherosclerosis as measured by CAC and FMD.  Women with PCOS had 
higher prevalence of CAC (none versus any)9-11 and more CAC (CAC <10 versus ≥10)8 and 
significantly lower FMD5,16,21,73   when compared to controls.   
There are many mechanisms that may explain the increase in CIMT among women with 
PCOS.  Studies suggested insulin,68 total cholesterol and LDL cholesterol,53,65 HDL 
cholesterol,45  triglycerides,65 CRP,74 serum interleukin-18,75 and abdominal obesity68,74 were 
associated with CIMT in women with PCOS.  Women with PCOS had higher insulin levels or 
insulin resistance compared to controls in all studies included in the meta-analysis except 
four.13,22,23,53  This analysis showed women with PCOS have greater CIMT than controls, but this 
analysis cannot evaluate the influence of CVD risk factors that are strongly associated with 
PCOS and CIMT.  Understanding the complexity of PCOS and the risk of CVD requires further 
classification of PCOS phenotypes and CVD risk factors in PCOS.    
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3.4.4 Conclusions  
The findings from the first meta-analysis on s ubclinical atherosclerosis in women with 
PCOS show greater CIMT in women with PCOS when compared to controls.  H eterogeneity 
was observed across studies, which may be due to that fact that PCOS is a common complex 
heterogeneous syndrome associated with CVD risk factors.  The results showed greater 
variation in the CIMT estimates across studies as the quality of the CIMT measurement 
decreased, which could partially explain inconsistencies in the literature that could be improved 
by using standardized ultrasound protocols and reporting detailed methods for CIMT. 
Identifying PCOS as a risk factor for CVD is difficult given the complexity of PCOS and 
the horizon for when CVD events occur with aging.  To date, most studies have been conducted 
in young women, but the risk of CVD may not be evident until later in life.  Large prospective 
studies with detailed PCOS phenotypic data and change in subclinical atherosclerosis are 
needed to provide a better estimate of the risk of CVD in women with PCOS.   
In the absence of these studies, PCOS is accompanied by CVD risk factors that place 
these women at an increased risk of atherosclerosis.  These findings enforce recommendations 
for screening and monitoring CVD risk factors in women with PCOS as endorsed by the 
Androgen Excess and PCOS society.30  This is of important public health significance as it will 
allow for the early identification of hypertension, type 2 diabetes and premature atherosclerosis 
in this high risk population.  
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3.6 TABLES AND FIGURES FOR CHAPTER THREE 
 
Figure 3.1 Diagram of the search strategy used to identify articles for the systematic literature 
review of carotid intima-media thickness (CIMT) in women with polycystic ovary syndrome and controls 
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Figure 3.2 PRISMA 2009 Flow Diagram 
 
 
 
 
Records identified through Ovid 
MEDLINE database searching  
(n =53) 
Additional records identified through 
EMBASE database searching  
(n =50) 
Records after duplicates removed 
(n = 56) 
Records screened  
(n =56) 
Records excluded  
(n =20) 
Full-text articles assessed 
for eligibility 
(n =36) 
Full-text articles excluded, 
4 studies did not have a 
control group, 2 studies 
did not report mean IMT 
between cases and 
controls, 4 not in English 
(n = 10) 
Studies included in 
qualitative synthesis  
(n =26) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =19) 
Studies excluded due to 
same first author/study 
population or did not report 
necessary statistics for 
meta-analysis 
(n = 8) 
A study published 
in 2011 added  
(n = 1) 
Modeled From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
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Table 3.1 Summary studies of CIMT in women with PCOS and controls for the qualitative review 
First 
Author, 
Date 
Control 
Population 
Controlled 
for Age 
and/or BMI 
N Age±SD BMI±SD 
Mean  
CIMT±SD 
(mm)  
p-value CIMT protocol Limitations 
Reason for 
not including 
in meta-
analysis 
Guzick D, 
1996 Community Age 
16 casesa 44.4±0.9c 32.7±2.3c 0.680±0.019c 
p=0.035 
Mean, left 
and right, 
near and 
far wall 
CCA, far 
wall bulb 
and ICA 
Did not adjust for BMI  
(p=0.01).  Hormone use was 
not addressed.  Only 16 of 
the 38 eligible cases 
participated.   
Same 
population 
as Talbott 
2000 16 controls 43.9±1.3
c 25.3±1.2c 0.630±0.012c 
Meyer C, 
2005 Community  NA 
100 casesa 32.7±1.8c 37.3±2.43c 0.55±0.01c 
p>0.05 
Mean, 
right, far 
wall CCA  
Did not 
report 
necessary 
statistics 
20 controls 33.2±2.3c 36.7±1.28c 0.54±0.01c   
Vryonidou 
A, 2005 
Patients 
seeking 
treatment for 
thyroid 
function and 
obesity 
Age and 
BMI 
75 casesa  23.9±5.4 27.3±7.0 0.58  (0.42-0.80) d p<0.001 Mean and Max, left 
and right, 
far wall 
CCA 
Did not give standard 
deviation or error for CIMT 
or the exact p-value.  Did not 
specify if they were taking 
hormones.   
Did not 
report 
necessary 
statistics 55 controls 24.7±5.3 26.3±7.7 
0.47 
 (0.38-0.63)d  
Carmina E, 
2006 NA 
Age and 
Weight 
50 casesa 25.2±1c 28.7±0.8c 0.50±0.01c   
p<0.01  
Mean, left 
and right, 
near and 
far walls 
CCA 
Did not take into account 
hormone use.   
Included 
Carmina 
2009 50 controls  25.1±0.7c 28.5±0.5c 0.41±0.01c 
Cascella T, 
2006 NA 
Age and 
BMI 
50 casesb 21.9±2.7 24.6±2.5 0.50±0.07 
p<0.001 
Mean, left 
and right, 
far wall 
CCA 
Did not mention if controls 
were off hormones. 
Included 
Cascella 
2008 50 controls 22.2±2.8 24.4±2.8 0.40±0.05 
aNIH PCOS Criteria; bRotterdam PCOS Criteria; cData expressed as Standard Error (SE); dData expressed as median (minimum-maximum); NA, Not Addressed; 
CCA, Common carotid artery; Bif, Carotid bifurcation; ICA, Internal carotid artery; P values are cases versus controls 
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                     Table 3.1 Continued 
First 
Author, 
Date 
Control 
Population 
Controlled 
for Age 
and/or BMI 
N Age±SD BMI±SD 
Mean  
CIMT±SD 
(mm) 
p-value CIMT protocol Limitations 
Rational for 
not including 
in meta-
analysis 
Erdogan 
M, 2008 NA  NA 
68 casesb 24.3±5.4  24.4±5.4 
Right  
0.42±0.50  p>0.05 
NA No description of the CIMT definition and protocol.   
Included 
Erdogan 
2009 
Left  
0.43±0.56 p>0.05 
26 controls 26.4±5.7 23.4±5.0 
Right 
0.44±0.56 
 Left   
0.44±0.77 
Adali E, 
2010 
Outpatient 
clinic Age 
24 
overweight 
or obese 
casesb 
26.7±2.2 29.7±3.6 0.04±0.01 
p>0.05 
Mean of 
left and 
right CCA , 
average   
of 5 
measure-
ments 
Split up cases so they might 
be underpowered. Did not 
mention smoking status.  
Obese cases BMI 
significantly higher than lean 
cases and controls (P<0.05). 
Unusual 
CIMT values 26 
nonobese 
casesb 
24.7±2.9 24.4±4.2 0.03±0.01 
25 controls 25.0±2.3 23.9±4.0 0.03±0.01 
Pamuk 
2010 
Healthy 
hospital staff 
Age and 
BMI 
35 casesb 26  (18-35)d 
29.7  
(23.9-
34.4)d 
0.52 (0.45-0.72)d 
0.51 
Right and 
left CCA, 
average   
of 5 
measure-
ments 
 
Did not 
report 
necessary 
statistics 
31 controls 27  (18-33)d 
28.4  
(23.1-
33.8)d 
0.49 (0.40-0.71)d 
 
aNIH PCOS Criteria; bRotterdam PCOS Criteria; cData expressed as Standard Error (SE); dData expressed as median (minimum-maximum); NA, Not Addressed; 
CCA, Common carotid artery; Bif, Carotid bifurcation; ICA, Internal carotid artery; P values are cases versus controls 
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Table 3.2 Summary of studies of CIMT in women with PCOS and controls for the meta-analysis 
First 
Author, 
Date 
Control 
Population 
Controlled 
for Age 
and/or 
BMI 
N Age±SD BMI±SD Mean CIMT±SD (mm) p-value 
Segment(s) 
used to 
measure CIMT 
CIMT protocol 
Talbott E, 
2000 
Community Age and BMI 
125 
casesa 
 37.5±6.2c 30.1±0.7c Age-BMI Adjusted (CI)   
CCA, Bif, ICA 
Mean, left and right, near 
and far walls, Intra-class 
correlation coefficient 0.86 
Overall 
(n=125) 
 0.7  
(0.68-0.73)  p=0.299 
30-44 y 
(n=78) 
0.65 
 (0.62-0.69) p=0.565 
≥ 45 y 
(n=47) 
0.77 
 (0.74-0.81) p=0.005 
142 
controls 
39.0±6.2c 26.5±0.5c Overall 
(n=142) 
0.67  
(0.65-0.69) 
 
30-44 y 
(n=82) 
0.64  
(0.61-0.67) 
≥ 45 y 
(n=60) 
0.71  
(0.68-0.75) 
Lakhani  
K, 2004 
Staff 
members 
Age and 
BMI 
19 
PCOSb 29.2±4.0  31.3±8.2  0.54±0.11 0.53±0.09
d p=0.006, p=0.034d 
CCA, Bif 
Mean, right side, CCA and 
Bif reported separately, 
intra-observer coefficient 
of variation (CV) 8% 
 
12 PCO 27.7±4.0 22.5±3.8 0.51±0.18 0.50±0.15
d p=0.038, p=0.841d 
 12 
controls 27.5±4.0 24.2±3.4 0.40±0.09 0.44±0.09
d   
Orio F, 
2004 
NA Age and BMI 
30 
casesb 22.2±2.5 22.4±2.1 0.53±0.09
e  
p<0.05 CCA 
Mean, right and left, far 
wall, intra-observer CV 
7% and inter-observer 
CV12%. 30 controls 22.6±2.3 22.1±1.8 0.39±0.08
e 
aNIH PCOS Criteria; bRotterdam PCOS Criteria; cData expressed as Standard Error (SE); dCIMT adjusted for age, systolic and diastolic BP, BMI, cholesterol 
and insulin; eAdjusted for age, BMI, waist to hip ratio, smoking status, glucose and insulin levels, FAI, lipid profile, Hcy concentrations, and SBP and DBP; 
fAndrogen Excess Society (AES) PC OS criteria; *Randomized clinical trial; NA, Not Addressed; CCA, Common carotid artery; Bif, Carotid bifurcation; ICA, 
Internal carotid artery; P values are cases versus controls 
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Table 3.2 Continued 
 
First 
Author, 
Date 
Control 
Population 
Controlled 
for Age 
and/or BMI 
N Age±SD BMI±SD 
Mean  
CIMT±SD 
(mm) 
p-value Segment(s) used to measure CIMT CIMT protocol 
Vural B, 
2005 
Medical 
students and 
nurses 
Age 
43 casesb 21.4±1.8 23.4±4.7 0.75±0.11  
p<0.001 CCA 
Left and right, near 
and far walls, intra-
observer error <0.03 
mm 
43 controls 20.8±2.2 21.5±3 0.61±0.11 
Alexan-
draki K, 
2006 
Doctors and 
medical 
students 
Age and 
BMI 
27 casesa 25.4±0.8c 27.42±1.1c 0.49±0.01c   
 p=0.19 CCA, Bif, ICA Mean, left and right, far wall , one reader 27 controls 27.3±0.8c 25.05±1.2c 0.51±0.02c 
Luque-
Ramirez 
M, 2007 
12 patients for 
obesity 
problems, 8 
healthy controls 
  
40 casesa 24.5±5.8 29.4±6.3 0.41±0.11 
p=0.005 CCA Left, far wall, intra-observer CV 10.8% 20 controls 27.2±6.8 28.2±6.9 0.33±0.08 
Cascella 
T, 2008 
NA Age and BMI 
200 casesb 24.6±3.2  28.5±2.8  0.46±0.16   
 p<0.001 CCA 
Mean, left and right, 
far wall, intra-
observer CV 7.0% 100 controls 24.0±2.8 28.8±2.7 0.38±0.09 
Costa L, 
2008 NA   
57 casesb 25.5±5.3  27.6±5.8 0.52±0.08  
p=0.35 CCA  Mean, left and right, far wall, one reader 37 controls 26.6±5.4 26.7±4.9 0.53±0.08 
Heutling 
D, 2008* 
Public 
advertising   
83 casesb 24.8±4.7  30.4±5.9  0.48±0.07 
p<0.001 CCA 
Mean, left and right, 
far wall, intra-
observer CV 6.8% 39 controls 27.8±5.6  29.1±4.8 0.42±0.05 
Karadeniz 
M, 2008 
Patients Age 
Casesb HOMA-
IR>1.75 (n=37) 
 
 23.8±5.5  25.6±5.6  
Right: 
0.41±0.05 p>0.05 
CCA NA 
Left: 0.43±0.06 p>0.05 
Casesb HOMA-
IR<1.75 (n=21)  24.9±5.1 22.2±4.1 
Right: 
0.43±0.05 p>0.05 
Left: 0.45±0.06 p>0.05 
25 controls 27.2±4.2 23.4±5.2 
Right: 
0.44±0.05 
 Left: 0.44±0.05 
aNIH PCOS Criteria; bRotterdam PCOS Criteria; cData expressed as Standard Error (SE); dCIMT adjusted for age, systolic and diastolic BP, BMI, cholesterol 
and insulin; eAdjusted for age, BMI, waist to hip ratio, smoking status, glucose and insulin levels, FAI, lipid profile, Hcy concentrations, and SBP and DBP; 
fAndrogen Excess Society (AES) PC OS criteria; *Randomized clinical trial; NA, Not Addressed; CCA, Common carotid artery; Bif, Carotid bifurcation; ICA, 
Internal carotid artery; P values are cases versus controls 
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Table 3.2 Continued 
 
First 
Author, 
Date 
Control 
Population 
Controlled for 
Age and/or BMI N Age±SD BMI±SD 
Mean  
CIMT±SD 
(mm) 
p-value 
Segment(s) 
used to 
measure CIMT 
CIMT protocol 
Saha S, 
2008 Staff members   30 cases
a 26.1±4.2 25.8±4.6 0.63±0.19 p<0.001 CCA, Bif, ICA Mean, left and right, NS 
30 controls 28.7±7.1 22.0±3.0 0.44±0.05 
Trakakis 
E, 2008 
Nurses and 
medical 
students 
  
53 casesb 26.1±5.5 28.7±7.1 
Right: 0.67±0.15 p<0.0001 
CCA, ICA 
Mean IMT, left and 
right, near and far 
wall 
Left: 0.68±0.13 p<0.0001 
53 controls 25.4±4.7 28.7±7.1 
Right: 0.46±0.16 
 Left: 0.42±0.16 
Arikan S, 
2009 
Staff and 
medical 
students 
Age and BMI 
39 casesb  22.8±5.5 21.5±6.5 0.45±0.82 
p>0.05 CCA 
Mean, left and right, 
far wall, one 
technician 30 controls 24.6±4.2 20.9±6.0 0.44±0.11 
Carmina 
E, 2009 Family 
members of 
staff 
Age and weight 
95 casesf 24.2±3 27.6±5.8 0.61±0.18 
p< 0.01 CCA 
Mean average of 10 
measurements of 
left and right far 
wall, intra-observer 
CV <7.0% 
90 controls 23.9±3 27.5±3 0.53±0.15 
Ciccone 
M, 2009 
NA Age 
29 casesb 22.0±3.8 26.3±4.5 0.651±0.59 
p>0.05 CCA, ICA, Bif 
Mean of average of 
3 measures from 
right and left, plaque 
free segments, one 
technician 26 controls 22.0±3.8 20.5±1.6 0.637±0.133 
Soares G, 
2009 Basic health 
clinic Age and BMI 
40 casesb 24.5±3.8 22.7±3.3 0.44±0.10 
p=0.41 CCA 
Mean of average of 
4 measures of right 
CCA 50 controls 24.5±5.1 23.1±3.2 0.42±0.09 
Erdogan 
M, 2009 
Outpatient 
clinic Age and BMI 
88 casesb 24.1±1.32 24.4±4.1 
Right: 0.74±0.59 
p>0.05 CCA NA 
Left: 0.73±0.80 
119 controls 25.0±2.1 23.5±4.1 Right: 0.74±0.61 
Left: 0.74±0.60 
aNIH PCOS Criteria; bRotterdam PCOS Criteria; cData expressed as Standard Error (SE); dCIMT adjusted for age, systolic and diastolic BP, BMI, cholesterol 
and insulin; eAdjusted for age, BMI, waist to hip ratio, smoking status, glucose and insulin levels, FAI, lipid profile, Hcy concentrations, and SBP and DBP; 
fAndrogen Excess Society (AES) PCOS criteria; *Randomized clinical trial; NA, Not Addressed; CCA, Common carotid artery; Bif, Carotid bifurcation; ICA, 
Internal carotid artery; P values are cases versus controls 
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Table 3.2 Continued 
 
First 
Author, 
Date 
Control 
Population 
Controlled for 
Age and/or BMI N Age±SD BMI±SD 
Mean  
CIMT±SD 
(mm) 
p-value 
Segment(s) 
used to 
measure 
CIMT 
CIMT protocol 
Ketel I, 
2010 
Clinic, local 
newspaper 
advertisements 
Age and weight 
22 lean casesb 28.6±4.5 22.0±2.2 0.53±0.08 
p>0.05 CCA Right side, mean of 3 measurements 
18 obese casesb 30.3±4.2 36.2±5.9 0.56±0.17 
17 lean controls 27.7±5.3 22.2±1.7 0.48±0.07 
13 obese controls 28.6±5.3 40.5±7.0 0.60±0.11 
Pepene C, 
2011 NA Age 
64 casesf 28.6±5.4c 29.9±0.8c 0.57±0.02c 
p=0.323 CCA, Bif, ICA 
Single max CIMT, 
left and right, one 
tech, CV 5% 20 controls 28.6±5.5c 26.3±1.3c 0.64±0.06c 
aNIH PCOS Criteria; bRotterdam PCOS Criteria; cData expressed as Standard Error (SE); dCIMT adjusted for age, systolic and diastolic BP, BMI, cholesterol 
and insulin; eAdjusted for age, BMI, waist to hip ratio, smoking status, glucose and insulin levels, FAI, lipid profile, Hcy concentrations, and SBP and DBP; 
fAndrogen Excess Society (AES) PCOS criteria; *Randomized clinical trial; NA, Not Addressed; CCA, Common carotid artery; Bif, Carotid bifurcation; ICA, 
Internal carotid artery; P values are cases versus controls 
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Figure 3.3 Funnel plot to assess publication bias among the highest quality studies: random effects model 
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Figure 3.4 Forest plot of studies that reported a reproducibility statistic and used the left and right CCA for CIMT 
 
 
 
Figure 3.5 Forest plot of studies that reported a reproducibility statistic and used the left and right CCA for CIMT 
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Lower Upper 
in means limit limit p-Value Cases Controls
Talbott 2000 30-44 y 0.010 -0.024 0.044 0.564 78 82
Talbott 2000 >=45 y 0.060 0.019 0.101 0.004 47 60
Orio 2004 0.140 0.097 0.183 0.000 30 30
Vural 2005 0.138 0.093 0.183 0.000 43 43
Cascella 2008 0.080 0.046 0.114 0.000 200 100
Heutling 2008 0.060 0.036 0.084 0.000 83 39
Carmina 2009 0.080 0.032 0.128 0.001 95 90
Pepene 2011 -0.063 -0.187 0.061 0.320 64 20
0.072 0.040 0.105 0.000 640 464
-1.00 -0.50 0.00 0.50 1.00
Controls Higher CIMT Cases Higher CIMT
             
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Lower Upper 
in means limit limit p-Value Cases Controls
Lakhani 2004 0.090 0.025 0.155 0.007 19 12
Luque-Ramirez 2007 0.080 0.026 0.134 0.004 40 20
0.084 0.042 0.126 0.000 59 32
-1.00 -0.50 0.00 0.50 1.00
Controls Higher CIMT Cases Higher CIMT
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Figure 3.6 Forest plot of studies that did not report a reproducibility statistic and used the left and right CCA for CIMT 
 
Figure 3.7 Forest plot of studies that did not report a reproducibility statistic and used the left and right CCA for CIMT 
 
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Lower Upper 
in means limit limit p-Value Cases Controls
Alexandraki 2006 -0.020 -0.050 0.010 0.184 27 27
Costa 2008 -0.010 -0.043 0.023 0.554 57 37
Saha 2008 0.190 0.120 0.260 0.000 30 30
Arikan 2009 0.010 -0.286 0.306 0.947 39 30
Ciccone 2009 0.014 -0.218 0.246 0.906 29 26
0.041 -0.038 0.120 0.310 182 150
-1.00 -0.50 0.00 0.50 1.00
Controls Higher CIMT Cases Higher CIMT
                
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Lower Upper 
in means limit limit p-Value Cases Controls
Karadeniz 2008 -0.003 -0.031 0.025 0.835 21 25
Trakakis 2008 0.211 0.152 0.271 0.000 53 53
Soares 2009 0.020 -0.019 0.059 0.319 40 50
Erdogan 2009 -0.002 -0.168 0.164 0.981 88 119
Ketel 2010 Lean 0.050 0.002 0.098 0.041 22 17
Ketel 2010 Obese -0.040 -0.146 0.066 0.458 18 13
0.045 -0.020 0.111 0.173 242 277
-1.00 -0.50 0.00 0.50 1.00
Controls Higher CIMT Cases Higher CIMT
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Table 3.3 PCOS and CIMT meta-analysis results for random effects models by quality of CIMT measurement 
Random Effects Model Number  of Studies 
Point 
Estimate SE 95% CI P-value 
Heterogeneity* 
χ2 (p-value) I2 
1 Studies that reported reproducibility and 
used the right and left CCA for CIMT 8 0.072 0.017 0.040, 0.105 <0.0001 36.818 (<0.0001) 80.988 
2 Studies that reported reproducibility and 
used one CCA for CIMT 2 0.084 0.021 0.042, 0.126 <0.0001 0.054 (0.817) 0.000 
3 Studies that did not report reproducibility 
and used the right and left CCA for CIMT 5 0.041 0.040 -0.038, 0.120 0.310 30.113 (<0.0001) 86.717 
4 Studies that did not report reproducibility 
and used one CCA for CIMT 6 0.045 0.033 -0.020, 0.111 0.173 43.575 (<0.0001) 88.526 
 All Studies 21 0.059 0.014 0.031, 0.088 <0.0001 144.804 (<0.0001) 86.188 
SE: Standard Error; CI: Confidence Interval; *heterogeneity estimates based on fixed effects model, χ2 from Q-value 
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4.0  COMPLEMENT PROTEIN C3 AND CORONARY ARTERY CALCIUM IN MIDDLE-
AGED WOMEN WITH POLYCYSTIC OVARY SYNDROME AND CONTROLS 
4.1 INTRODUCTION 
Polycystic ovary syndrome (PCOS) affects 6-10% of women in the United States and is 
the most common reproductive endocrine disorder.1,2  Women with PCOS experience acne, 
excessive hair, weight gain and i rregular periods.  These women also have an i ncrease in 
cardiovascular disease (CVD) risk factors including insulin resistance,3 dyslipidemia,4 abdominal 
obesity,5 type 2 diabetes6 and inflammation.7  There is limited evidence of an increased risk in 
CVD events, but studies show women with PCOS have an increased risk of subclinical 
atherosclerosis as measured by coronary artery calcification (CAC),8-11 and adverse vascular 
structural and functional changes measured by carotid artery intima-media thickness12-19 and 
flow mediated dilation5,20-22 when compared to controls.   
The exact roles of PCOS related factors involved in atherosclerosis are inadequately 
defined and may have long-term effects on the progression of atherosclerotic lesions.  Recent 
studies suggest that PCOS is a l ow-grade inflammatory state, which is concerning since 
atherosclerosis is classified as a vascular inflammatory disease.  The process involves 
inflammatory components triggering, initiating and pr omoting atherosclerosis.23-25  Pro-
inflammatory response proteins have been found in atherosclerotic lesions26-28 and plaques.29   
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 The inflammatory markers include those of the innate immune system, which provides 
immediate defense against pathogens in part through the complement cascade.  The 
complement system contains over 30 complement proteins; however, complement protein C3 
(C3) is of particular interest because it is the central component in the complement cascade.  
The classical, alternative and m annose-binding lectin pathways of the inflammatory response 
converge at C3, which cleaves C3 and e licits the inflammatory response.  The inflammatory 
response is essential to protect the body for disease and injury, but has the potential to promote 
vascular damage under certain circumstances.23,30  C3 is a pr oposed inflammatory marker of 
atherosclerosis as complement levels have been elevated in people with CVD31-33 and C3 has 
been associated with tissue damage at the site of myocardial infarctions.34   
Currently, the association of C3 and subclinical measures of atherosclerosis in the 
general population is unknown.  The association of C3 with subclinical CVD measures has been 
investigated in women with systemic lupus erythematosus (SLE), which is also a high CVD risk 
population.  High circulating C3 levels in young women with SLE were associated with 
subclinical CVD measures including an increased prevalence of coronary artery calcium 
(CAC)35 and vascular stiffness measured by pulse wave velocity (PWV).36,37   
No investigation has been completed of the association between C3, CVD risk factors, 
and atherosclerosis in middle-aged women with PCOS and controls.  The aim of this study was 
to determine whether circulating serum C3 levels are higher in women with PCOS compared to 
non-PCOS controls, and whether C3 levels are associated with traditional CVD risk factors and 
CAC in women with PCOS and non-PCOS controls.   
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4.2 METHODS 
4.2.1 Study Population 
 This study is based on the third phase of the Cardiovascular Health and Risk 
Measurement Study (CHARM III) that occurred between 2001 and 2003.  There were a total of 
319 women (151 women with PCOS and 168 controls) in CHARM III; however, this present 
analysis includes 132 women with PCOS and 155 controls aged 35-62 years old in which stored 
serum was available in 2010.  The CHARM recruitment and methodology has previously been 
described.11,38  Briefly, investigators identified women aged 19-55 years old diagnosed with 
PCOS between 1970 and 1993 through medical records in the Division of Reproductive 
Endocrinology at Magee-Women’s Hospital (Pittsburgh, PA).  Investigators used NIH criteria to 
define PCOS.39  Investigators matched PCOS cases to neighborhood controls by age (±5 years) 
and race using voter’s registration tapes and the Cole’s Cross Reference Directory of 
Households from 1993.  The University of Pittsburgh institutional review board approved the 
protocols and all participants gave consent before enrolling.   
4.2.2 Data Collection 
 The clinical visit and assessments of participant characteristics have been previously 
described.8,11,38  In brief,  investigators collected medical, surgical, menstrual and reproductive 
history, medication use, lifestyle, anthropometric measurements, blood pressure and serum 
concentrations of total cholesterol, HDL-C, LDL-C, triglycerides, fasting glucose and insulin, and 
hormones that included sex hormone binding globulin (SHBG), luteinizing hormone (LH), follicle 
stimulating hormone (FSH), total testosterone, progesterone and estradiol.  The quantitative 
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insulin sensitivity check index (QUICKI) was also calculated (QUICKI= 1/[log fasting insulin 
concentration (µU/mL) + log glucose concentration (mg/dL)]).40  QUICKI is a measure of insulin 
sensitivity where lower values indicate insulin resistance.  
 Blood serum samples were frozen during CHARM III in 2001-2003 and stored at the 
University of Pittsburgh Graduate School of Public Health.  In 2010, Quest Diagnostics 
(Pittsburgh, PA) collected 287 stored serum samples and applied an immunoturbidimetric assay 
(C3c Serum Complement Assay, ID 44859W) with a Roche Integra System to measure C3 
levels.  The reference range for C3 from the Quest laboratory was 90-180 mg/dL.  Quality 
control measures for this assay include a monthly audit comparing data bias and precision 
against other Quest laboratories operating the same platform and a guarantee through 
regulated College of American Pathologists (CAP) and New York State Proficiency.  
4.2.3 Coronary Artery Calcium Assessment 
 The participants underwent an electron beam computed tomography (EBCT) of the heart 
and aorta to measure coronary artery calcification at the University of Pittsburgh Medical Center 
Preventive Heart Care Center.  Methods have been previously described.11  Briefly, the 
radiology and computer tomography technicians (RT/CT) were blinded to case control status 
and performed one scan per participant using the Imatron C-150 Ultrafast CT scanner (Imatron, 
South San Francisco, CA).  The RT/CT technician scanned 30-40 contiguous images 3 mm 
from the aortic root to the apex of the heart with a 100 millisecond exposure time.  Images were 
taken at the same phase of cardiac cycle, approximately 60% of the R-R interval.   
 Coronary calcium scores were computed using the base value region of interest 
computer software program (AccuImage, Diagnostics Corp., San Francisco, CA).  Calcification 
was defined as pixels greater than 130 Houndsfield units and 1 mm2 within an operator-defined 
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region of interest (ROI) in each 3 mm thick image.  The Agatston method was used to calculate 
the calcium score for each ROI by multiplying the area of significant pixels by a grade number 
(1-4) indicative of the peak computerized tomography number (Hounsfield unit).41  The 
individual ROI’s were summed for a total coronary calcium score.   
4.2.4 Statistical Analysis 
 This cross-sectional analysis of serum C3 levels and CAC contained 132 women with 
PCOS and 155 controls aged 35-62 years old.  To account for the original age-matched design, 
the descriptive and correlation analyses were performed stratified by age groups <45 years old 
and ≥45 years old, and the logistic regression models were adjusted for age.  Participant 
characteristics were calculated using descriptive statistics for women with PCOS and controls, 
and were compared using Chi-square tests or Fisher’s exact test for categorical data and 
independent t-tests for normally distributed continuous variables or the Mann-Whitney U test for 
non-normally distributed variables.  Pearson correlations were used to determine associations 
between C3 and CVD risk factors in women with PCOS and controls.  Women using hormone 
replacement therapy or oral contraceptives were excluded when analyzing hormone levels so 
the results were not influenced by hormone use.   
 The association between C3 and CAC was determined by logistic regression analyses of 
CAC as a binary (presence of CAC Agatston score ≤0 vs. >0) as well as an ordinal variable 
(three group CAC categories) adjusting for PCOS status, age and significant CVD risk factors.  
Three categories of CAC: 0, 1-10, and ≥11 were created based from published guidelines for 
five categories of CAC (0, 1-10, 11-100, 101-400, 401+).42  The last three groups were 
combined since few subjects had a CAC score greater than 100.  To address the original age-
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matched design, a sensitivity analysis was conducted using conditional logistic regression of the 
presence of CAC (Agatston score ≤0 vs. >0) with the 47 original age-matched pairs.   
For all regression analyses, insulin and glucose levels were categorized into quartiles 
and C3 was expressed as a unit of 10 mg/dL.  All participant factors with a significant univariate 
association of p<0.20 with CAC were evaluated in a forward stepwise method for the 
multivariable regression models.  All first order interactions with C3 and case control status were 
tested.  The test of parallel lines was performed for the ordinal logistic regression analyses to 
check the proportional odds assumption that the slope coefficients are the same across pairs of 
CAC groups.   
Variables were presented as means±standard deviations or medians (inter-quartile 
range), odds ratios (OR) and 95% confidence intervals (CI). The level of statistical significance 
was a 2-sided p-value of <0.05.  All analyses were done using PASW (version 18; IBM SPSS 
Inc., Chicago, IL, USA). 
4.3 RESULTS 
 There were 55 women with PCOS and 39 controls that were <45 years old, and 77 
women with PCOS and 116 controls that were ≥45 years old.  In women <45 years old, women 
with PCOS and controls did not differ with respect to age (41.96±2.09 compared to 42.00±2.25 
years old, p=0.92, respectively) and BMI (31.41±7.13 kg/m2 compared to 29.23±6.61 kg/m2, 
p=0.14, respectively) (Table 4.1).  However in women ≥45 years old, women with PCOS were 
significantly younger than controls (50.44±3.79 compared to 51.75±4.21years old, p=0.03, 
respectively) and had  a higher BMI than controls (31.53±7.91 kg/m2 compared to 28.34±5.94 
kg/m2, p=0.002, respectively).  Women with PCOS had significantly larger waist-to-hip ratio and 
 66 
 
fasting insulin compared to controls among women <45 years.  Women with PCOS ≥45 years 
old had s ignificantly higher BMI, waist circumference, waist-to-hip ratio, fasting insulin, 
triglycerides and lower age, QUICKI and HDLc compared to controls.  C3 was higher, but not 
significantly different, in women with PCOS than controls <45 years old (171.20±36.87 mg/dL 
compared to 168.79±35.11 mg/dL, p= 0.76), and in women with PCOS than controls ≥45 years 
old (175.12±39.85 mg/dL compared to 169.06±36.81 mg/dL, p= 0.28).   
Significant differences were seen in levels of total testosterone and SHBG in women <45 
years old and in SHBG, luteinizing hormone, FSH in women ≥45 years old, excluding women 
currently using HRT or OCs (Table 4.2).  In women <45 years old, women with PCOS had 
higher total testosterone and lower SHBG than controls (p<0.05).  In women ≥45 years old, 
women with PCOS had had lower SHBG, LH, and FSH than controls (p<0.05).   
Women with PCOS and controls were similar with respect to categorical characteristics 
in women <45 years old; however in women ≥45 years old, women with PCOS were more 
obese (BMI≥30), and had more type 2 diabetics and fewer African American women compared 
to controls (Table 4.3).  The presence of CAC (>0), in CAC 10+ or in the CAC groups did not 
differ between women with PCOS and controls in women <45 years old (Table 4.4).  Conversely 
in women ≥45 years old, women with PCOS had more CAC >0 (64.9% versus 44.0%, p=0.004), 
CAC 10+ (35.1% versus 12.1%, p<0.001) and more women in higher CAC groups (p<0.0001) 
compared to controls. 
There were a few differences in C3 levels with respect to categorical variables within the 
age and PCOS and control subgroups (data not shown).  In controls <45 years old, the women 
currently using oral contraceptives had a higher C3 than the non-users, p=0.006.  In women 
with PCOS ≥45 years old, the thirteen type 2 diabetics had higher C3 than the non-diabetics, 
p=0.002.  In controls ≥45 years old, the African Americas had higher C3 than the Whites, 
p=0.03, and the three type 2 diabetics had higher C3 than the non-diabetics p=0.007.   
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Regardless of age groups or PCOS status, C3 positively correlated with BMI, waist 
circumference, waist-to-hip ratio, insulin, triglycerides and negatively correlated with QUICKI (all 
p<0.01) (Table 4.5).  Except in controls <45 years old, C3 positively correlated with glucose 
(p<0.01) and negatively with HDLc (p<0.01, p=0.05 in controls ≥45 years old).  C3 positively 
correlated with LDLc in women with PCOS and controls <45 years old (p<0.01) and with SBP in 
women with PCOS and controls ≥45 years old (p<0.01).  C3 negatively correlated with SHBG in 
all groups (p<0.02) (Table 4.6).  Estradiol negatively correlated with C3 in controls <45 years old 
(r=-0.25, p=0.04) and FSH positively correlated with C3 in women with PCOS <45 years old 
(r=0.29, p=0.04). 
 For the logistic and ordinal regression analysis, the significant variables associated with 
CAC included case control status, age, C3, BMI, insulin quartiles and African American race.  In 
the logistic regression analysis of the presence of CAC, a 10 mg/dL unit increase in C3 was 
associated with the presence of CAC after adjusting for case control status and age (OR 1.39, 
95% CI [1.27, 1.52], p<0.0001), when additionally adjusting for insulin quartiles (OR=1.26, 95% 
CI [1.14, 1.39], p=0.011) or was borderline significant when adjusting for BMI (OR=1.14, 95% CI 
[1.03, 1.27], p=0.072) (Table 4.7).  C3 was significantly related to the presence of CAC 
(OR=1.12, 95% CI [1.00, 1.25], p=0.049) in the fully adjusted model that included age, PCOS 
status, BMI, insulin quartiles, and African American race.   
 In ordinal logistic regression analysis adjusting for case control status and age, the 
expected odds of a higher CAC category for a ten unit increase in C3 (mg/dL) was 1.91 (95% CI 
[1.35, 2.71], p<0.0001), and remained significant after additionally adjusting for insulin quartiles 
(OR=1.14 (95% CI [1.08, 1.20], p<0.0001) or BMI (OR=1.09 (95% CI [1.03, 1.15], p=0.003) 
(Table 4.8).  The association between C3 and CAC was attenuated but borderline significant 
(OR=1.06 (95% CI [0.99, 1.12], p=0.082) in the fully adjusted model that included age, PCOS 
status, BMI, insulin quartiles, and African American race.   
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 There were no significant interactions between C3 and PCOS status with any variables 
in the binary and ordinal regression models.  In the ordinal logistic regression analyses, the test 
of parallel lines was not significant, which indicated the proportional odds assumption was met.  
All categorical variables were assessed as possible confounders in the fully adjusted regression 
models.  The only significant variable after adjusting for age and case control status was type 2 
diabetes.  C3 remained significantly associated with the presence of CAC after adjusting for 
age, case control status, BMI, African American race, and type 2 diabetes (OR=1.15, 95% CI 
[1.04, 1.29], p=0.008) (data not shown).  However, in the ordinal logistic regression analysis, the 
test of parallel lines was significant when type 2 diabetes was placed in the model instead of 
insulin, which indicated the proportional odds assumption was violated.  Thus, BMI and insulin 
were adjusted for in the regression analysis because they appeared to be more of a possible 
confounder than type 2 diabetes.   
From the 47 original age-matched pairs, 24 di scordant pairs were used for the 
conditional logistic regression of the presence of CAC (Table 4.9).  C3 was significantly related 
to the prevalence of CAC after adjusting for case control status (OR=1.29, 95% CI [1.01, 1.65], 
p=0.04) (Table 4.10).  This association of C3 and CAC was attenuated after adjustment for 
insulin quartiles (p=0.31) or BMI (p=0.47).  There was no evidence of an interaction with case 
control status and C3 (p=0.39).   
4.4 DISCUSSION 
 This is the first study to investigate complement protein C3, CVD risk factors and 
subclinical CVD in middle-aged women with PCOS and their respective controls.  Although not 
significant, women with PCOS had higher C3 levels when compared to controls in women <45 
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years old (p=0.76) and in women ≥45 years old (p=0.28).  C3 significantly correlated with 
traditional CVD risk factors and higher circulating C3 levels were associated with the presence 
of CAC and with increasing CAC.  Our results indicate that C3 may be a specific atherosclerotic 
inflammatory marker in women with PCOS and non-PCOS controls.   
This study reflected a trend of higher circulating C3 levels in women with PCOS when 
compared to controls in both age groups, which was more evident in women ≥45 years old.  
Similar to our results, Wu et al. found that C3 levels were higher, but not significantly different, 
between premenopausal women with PCOS and controls (2.1 g/L versus 1.8 g/L, p>0.05, 
respectively).43  They also showed C3 was positively correlated with insulin, homeostasis model 
assessment-insulin resistance (HOMA-IR) and triglycerides in women with PCOS, all p<0.05.  
Other studies have shown higher C3 levels in premenopausal women with PCOS compared to 
their control counterpart.  Oktenli et al. showed C3 levels were higher among non-obese women 
with PCOS compared to age and BMI-matched controls (1.4 g/L versus 1.0 g/L, p<0.001, 
respectively).44  Similarly, Yang et al. showed women with PCOS had higher C3 levels than 
controls (1.4 g/L versus 1.1 g/L, p<0.05, respectively), and remained higher among women with 
PCOS after stratifying by lean and obese participants.45  In addition to evaluating C3 levels, 
many studies have shown higher levels of circulating inflammatory markers such as C-reactive 
protein (CRP)7,46-48 and cytokines49,50 in women with PCOS when compared to controls.   
Complement levels are not traditionally evaluated in the diagnosis or treatment of PCOS.  
Complement C3 and C4 are circulating markers of inflammation that are routinely measured in 
the diagnosis and treatment of SLE.  C3 has correlated positively with subclinical CVD 
measures in women with SLE and is considered a SLE-specific risk factor for CVD.  Women 
with PCOS are also at increased risk of premature cardiovascular disease51 and are affected by 
many traditional CVD risk factors52 that could contribute to inflammation.  Recent studies 
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suggest PCOS is a low-grade inflammatory state48,53,54 similar to autoimmune diseases such as 
SLE and atherosclerosis in cardiovascular disease.   
Women with PCOS have a high prevalence of obesity and insulin resistance, which are 
also considered to have an underlying inflammatory process.55-57  Cytokines from adipose 
tissue58 and insulin resistant states59 can stimulate the synthesis of C3.  The liver is the main 
source of C3, but adipocytes secrete inflammatory cytokines and complement proteins including 
C3.58,60,61  These observations suggest that obesity and insulin resistance are sources of 
cytokines and complement that could exacerbate a chronic low grade inflammatory response.  
An additional complexity arises with a C3 cleavage product termed acylation-stimulating protein 
(ASP) that is involved in glucose and triglyceride metabolism in adipose tissue.62,63   
This present analysis showed that C3 had a strong relationship between insulin and 
BMI, and all of which had significant associations with CAC.  This finding is consistent with 
studies that showed C3 had the strongest correlations with insulin and various features of 
insulin resistance.31  Most women with PCOS are obese and insulin resistant,6,64 which could be 
linked by chronic inflammation.54  Studies have suggested C3 is a stronger inflammatory marker 
of insulin resistance than CRP in non-PCOS populations65-67 and in women with PCOS.45  
These present findings also indicate C3 could be a key inflammatory marker of obesity and 
insulin resistance in women with and without PCOS.   
A previous analysis of this study population showed a higher presence of CAC (10+) in 
women with PCOS,8 which is supported by studies evaluating CAC in premenopausal women 
with PCOS and controls.9,10  In this secondary analysis, circulating inflammatory marker 
complement C3 was also associated with CAC in these participants.  The association of C3 and 
CAC was partially explained by the combination of insulin and BMI, but remained significant.  In 
fully adjusted models, C3 was significantly related to the presence of CAC and borderline 
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significant in the association of increasing CAC groups.  This suggests C3 may be a specific 
inflammatory marker of atherosclerosis in women with PCOS and non-PCOS controls.   
Significant relationships between C3 and subclinical CVD measures including vascular 
stiffness, as measured by PWV, and CAC have been confirmed in SLE patients and are 
consistent with these findings in women with PCOS and controls with respect to CAC.  Among 
women with SLE, high C3 levels (>0.9 g/L) were associated with the prevalence of CAC (OR 
4.0, p=0.007) after adjusting for age.35  Increasing C3 levels were also associated with an 
increase in PWV36 and with the highest quartile of PWV (OR 1.02, 95% CI [1.00,1.04], p=0.03) 
in women with SLE.37  
Additional epidemiological studies have also suggested that C3 is an inflammatory CVD 
risk factor comparable to traditional CV risk factors,30,47 and a strong predictor of both initial48 
and recurrent49 CVD events.  Ajjan et al. showed C3 was a better predictor of coronary artery 
disease than CRP in both men and women, and those with higher C3 levels were three times 
more likely to develop coronary heart disease (CHD).32  This result was corroborated by Onat et 
al. who showed the odds of CHD was 3.5 for higher C3 levels,33 while Szeplaki et al. showed 
high C3 levels (≥1.8 g/L) predicted future vascular complications among women with existing 
severe CHD.68  These previous reports support the present findings that C3 strongly correlated 
with traditional CVD risk factors and CAC within this PCOS population and their respective 
controls.   
The elevation of circulating C3 in healthy and non-healthy individuals with CVD and the 
relation to subclinical measures suggests a potential mechanistic involvement of complement in 
the development of atherosclerosis.  Complement proteins could play a role in vascular 
dysfunction by deteriorating the mechanical integrity of the vascular wall, and over time this 
could lead to the formation and progression of an atherosclerotic lesion.37  Atherosclerotic 
lesions have been found to contain complement proteins including C3.69-71  Conventional 
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thought suggests that various complement activating substrates within atherosclerotic lesions 
activate complement leading to additional inflammation and further lesion progression.  Given 
the evidence, C3 may confer an increased risk of CVD by contributing to vascular stiffness, 
which normally occurs with age in healthy populations,72,73 and atherosclerosis. 
  A limitation to this study was the length of serum sample storage.  The samples were 
stored for an average of 9 years; however, Muscari et al. successfully evaluated C3 levels in 
samples stored for 7 years.74  Another limitation was that participants were lost to follow up from 
the original CHARM I visit.  However, this analysis included a large population of women with 
PCOS and controls and there was a wide range of age and BMI when compared to the 
literature.  Another strength was that the sensitivity analysis with a subset of the original age 
matched pairs showed that C3 was related to the presence of CAC after adjusting for case 
control status.  The cross-sectional design of this study limited the ability to determine causality; 
however previous prospective studies mentioned previously have shown C3 significantly 
predicted CVD events.  
Despite these limitations, this study remains the first to investigate C3 levels among 
middle-aged women with PCOS compared to controls and to investigate the association of C3 
with CVD risk factors and subclinical CVD.  Future studies are needed to confirm these results 
and could be further investigated by using other markers of subclinical atherosclerosis.  Studies 
have shown levels of C3 significantly decreased after administering an insulin-sensitizing 
medication for three months in women with PCOS44 and decreased with weight loss and 
physical activity in men.75  It would be interesting to evaluate whether reducing C3 has a 
beneficial effect on subclinical measures of atherosclerosis.   
In conclusion, there is evidence that circulating serum C3 is associated with subclinical 
cardiovascular disease.  Previous reports from this study population showed that PCOS was 
associated with CAC, but this analysis showed that C3 is also independently associated with 
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CAC.  Our results have important public health implications as this indicates C3 may be a  
specific inflammatory CVD risk marker in women with and without PCOS.  Further investigations 
of the inflammatory mechanisms behind the progression of atherosclerosis are needed to 
identify vulnerable subgroups at risk for CVD.  Ultimately, this could lead to targeted therapies to 
reduce inflammation and prevent the progression of atherosclerosis.   
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4.6 TABLES AND FIGURES FOR CHAPTER FOUR 
 
Table 4.1 Characteristics of cases and controls by age group 
  Age <45 Age ≥45 
  Cases (n=55) Controls (n=39) P-value Cases (n=77) Controls (n=116) P-value 
Age (yr) 41.96±2.09 42.00±2.25 0.92 50.44±3.79 51.75±4.21 0.03 
Complement C3 (mg/dL) 171.20±37.86 168.79±35.11 0.76 175.12±39.85 169.06±36.81 0.28 
BMI (Kg/m2)  31.41±7.13 29.23±6.61 0.14 31.53±7.91 28.34±5.94 0.002 
Waist Circumference (cm) 92.40±16.62 87.06±14.07 0.11 94.08±18.02 85.68±14.04 <0.0001 
Waist-to-Hip Ratio1 0.84±0.09 0.80±0.07 0.04 0.85±0.09 0.81±0.08 <0.0001 
SBP (mm Hg) 114.26±10.52 113.82±12.74 0.86 120.90±11.38 118.41±14.64 0.21 
DBP (mm Hg) 74.20±8.48 73.97±9.01 0.90 77.43±8.11 75.94±8.15 0.22 
Insulin (µU/mL)* 17.90  (10.10, 26.90) 
11.80  
(9.00, 19.60) 0.04‡ 
15.40  
(9.60, 24.30) 
10.90  
(8.40, 15.38) <0.0001‡ 
Glucose (mg/dL)* 90.00  (85.23, 97.00) 
89.18  
(85.00, 96.19) 0.94‡ 
93.00  
(86.50, 105.00) 
93.00  
(87.00, 98.62) 0.18‡ 
QUICKI 0.32±0.03 0.33±0.02 0.07 0.32±0.04 0.33±0.03 0.001 
Triglycerides (mg/dL)* 104.00  (73.00, 199.00) 
96.00  
(79.20, 127.00) 0.39‡ 
140.00  
(86.80, 233.00) 
115.00  
(77.93, 154.25) 0.02‡ 
Total Cholesterol (mg/dL) 201.07±38.75 194.74±31.91 0.40 214.43±47.00 214.28±35.16 0.98 
HDLc (mg/dL) 52.52±13.37 52.12±11.23 0.88 52.00±17.18 58.34±14.90 0.007 
LDLc (mg/dL)2 120.54±35.51 119.05±26.77 0.83 127.90±43.26 130.19±33.31 0.68 
Values are mean±SD or *median (Inter-Quartile Range: 25th, 75th percentile); ‡P-value by Mann-Whitney U test, otherwise by unpaired 
t test; 1) n=38 cases <45, n=76 cases ≥45; 2) n=75 cases age ≥45      
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Table 4.2 Hormones in cases and controls by age group (excluding women on OC or HRT) 
  Age <45 Age ≥45 
  Cases (n=48) Controls (n=32) P-value Cases (n=57) Controls (n=85) P-value 
Age (yr)* 41.87±2.17 41.81±2.41 0.91 50.44±3.62 51.29±3.95 0.19 
BMI (Kg/m2)* 31.95±7.33 28.50±6.11 0.03 32.41±7.89 28.41±6.24 0.001 
Total Testosterone 
(ng/dL)1 
25.94 (19.88, 45.39) 20.03 (19.88, 25.94) 0.005 23.05 (19.88, 46.11) 23.05 (19.88, 28.82) 0.39 
Sex Hormone 
Binding Globulin 
(nmol/mL) 
81.90 (53.43, 130.80) 129.35 (83.45, 177.05) 0.02 75.10 (54.50, 138.45) 126.60 (80.00, 189.30) 0.0005 
Luteinizing 
hormone-
(miU/mL)2 
7.55 (4.05, 11.88) 5.00 (2.60, 7.90) 0.08 11.90 (5.95, 21.90) 24.50 (6.92, 44.00) 0.0002 
FSH (mIU/ml)2 
5.45 (4.70, 6.78) 6.30 (3.90, 10.90) 0.51 14.50 (7.30, 34.30) 41.10 (12.10, 78.70) <0.0001 
Progesterone 
(ng/dL)1 
2.45 (1.60, 5.35) 4.25 (1.53, 41.30) 0.26 1.80 (1.30, 5.00) 1.50 (1.10, 2.68) 0.13 
Estradiol (pg/mL)3 
79.05 (55.55, 133.98) 76.50 (35.75, 123.85) 0.38 54.20 (35.55, 92.40) 40.30 (26.60, 90.85) 0.41 
Values are median (Inter-Quartile Range: 25th, 75th percentile) or  *mean±SD ; P-value by Mann-Whitney U test or t-test; 1) n=84 controls ≥45; 
2) n=31 controls <45, n=83 controls ≥45; 3) n=36 cases, 25 controls <45, n=45 cases, 72 controls ≥45     
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Table 4.3 Selected characteristics by age group  
  Age <45 Age ≥45 
Cases 
(n=55) 
n (%) 
Controls 
(n=39) 
n (%) 
P-value 
Cases 
(n=77) 
n (%) 
Controls 
(n=116) 
n (%) 
P-value 
High Complement C3  
(>180 mg/dL, Quest reference 
range 90-180 mg/dL) 25 (45.5) 14 (35.9) 0.35 32 (42.1) 39 (33.6) 0.23 
African American Race 6 (10.9) 8 (20.5) 0.20 7 (9.1) 23 (19.8) 0.04 
Current Smoker  8 (14.5) 9 (23.1) 0.29 15 (19.5) 13 (11.2) 0.11 
Current OC user 6 (10.9) 5 (12.8) 1.0* 4 (5.3) 5 (4.3) 0.74* 
Current HRT user 1 (1.8) 2 (5.3) 0.57* 16 (20.8) 26 (22.4) 0.79 
Never been pregnant  11 (20.0) 7 (17.9) 0.80 20 (26.0) 21 (18.1) 0.19 
Postmenopausal  
(no period in the last 12 months)  5 (9.1) 5 (12.8) 0.74* 30 (39.0) 58 (50.0) 0.13 
Obese (BMI ≥30) 30 (54.5) 15 (38.5) 0.12 45 (58.4) 42 (36.2) 0.002 
Hypertension Treated 9 (16.4) 3 (7.7) 0.35* 23 (29.9) 24 (20.7) 0.15 
Type 2 Diabetes, 
Doctor Diagnosed 5 (9.1) 1 (2.6) 0.40* 12 (21.4) 3 (4.8) 0.006 
Type 2 Diabetes  
(doctor diagnosed) or  
glucose ≥126 (mg/dL) 
5 (9.1) 2 (5.1) 0.70* 13 (16.9) 4 (3.4) 0.001 
Values are number (percent); P-value between cases and controls by chi-square test or *Fisher's Exact test 
Table 4.4 Coronary artery calcium by age group 
  Age <45 Age ≥45 
Cases (n=55) 
n (%) 
Controls (n=39) 
n (%) P-value 
Cases (n=77) 
n (%) 
Controls (n=116) 
n (%) P-value 
CAC Any  29 (52.7) 15 (38.5) 0.20 50 (64.9) 51 (44.0) 0.004 
CAC 10+  15 (27.3) 8 (20.5) 0.50 27 (35.1) 14 (12.1) <0.0001 
CAC groups        
 0 26 (47.3) 24 (61.5) 0.40 27 (35.1) 65 (56.0) <0.0001 
 1-10 14 (25.5) 7 (17.9)  23 (29.9) 37 (31.9)  
 ≥11 15 (27.3) 8 (20.5)  27 (35.1) 14 (12.0)  
Values are number (percent); CAC expressed as Agatston Score; P-value between cases and controls by 
chi-square test 
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Table 4.5 Spearman's correlations with complement C3 by age group 
  Age <45  Age ≥45 
  Cases (n=55) Controls (n=39) Cases (n=77) Controls (n=116) 
Age (yr) ‐0.03 (0.83) 0.24 (0.14) 0.08 (0.50) 0.20 (0.03) 
BMI (Kg/m2)  0.59 (<0.0001) 0.52 (0.0006) 0.69 (<0.0001) 0.58 (<0.0001) 
Waist Circumference (cm) 0.60 (<0.0001) 0.60 (<0.0001) 0.71 (<0.0001) 0.64 (<0.0001) 
Waist-to-Hip Ratio1 0.46 (0.0005) 0.52 (0.0007) 0.56 (<0.0001) 0.55 (<0.0001) 
SBP (mm Hg) 0.21 (0.12) 0.20 (0.22) 0.27 (0.02) 0.37 (<0.0001) 
DBP (mm Hg) 0.22 (0.10) 0.25 (0.13) 0.21 (0.07) 0.44 (<0.0001) 
Insulin (µU/mL)* 0.58 (<0.0001) 0.63 (<0.0001) 0.64 (<0.0001) 0.57 (<0.0001) 
Glucose (mg/dL)* 0.32 (0.02) 0.006 (0.97) 0.50 (<0.0001) 0.33 (0.0003) 
QUICKI ‐0.59 (<0.0001) ‐0.60 (<0.0001) ‐0.66 (<0.0001) ‐0.57 (<0.0001) 
Triglycerides (mg/dL)* 0.55 (<0.0001) 0.36 (0.03) 0.50 (<0.0001) 0.34 (0.0002) 
Total Cholesterol (mg/dL) 0.52 (<0.0001) 0.58 (0.0001) 0.25 (0.03) 0.16 (0.09) 
HDLc (mg/dL) ‐0.30 (0.03) ‐0.10 (0.56) ‐0.38 (0.001) ‐0.18 (0.05) 
LDLc (mg/dL)2 0.36 (0.008) 0.50 (0.001) 0.21 (0.08) 0.10 (0.28) 
Values are Spearman's rho (p-value)   
Table 4.6 Spearman's correlations of complement C3 and hormones among cases and controls by age 
groups (excluding women on OC or HRT) 
  Age <45  Age ≥45 
  Cases (n=55) Controls (n=39) Cases (n=77) Controls (n=116) 
Total Testosterone (ng/dL)1 ‐0.09 (0.55) ‐0.07 (0.71) 0.03 (0.85) 0.04 (0.72) 
Sex Hormone Binding Globulin 
(nmol/mL) 
‐0.46 (0.001) ‐0.42 (0.02) ‐0.48 (0.0002) ‐0.50 (<0.0001) 
Luteinizing Hormone (miU/mL)2 
‐0.06 (0.67) 0.25 (0.18) ‐0.20 (0.13) 0.17 (0.12) 
Follicle Stimulating Hormone 
(mIU/ml)2 
0.29 (0.04) 0.27 (0.14) ‐0.07 (0.59) 0.08 (0.47) 
Progesterone (ng/dL)1 ‐0.13 (0.38) ‐0.09 (0.63) ‐0.13 (0.35) ‐0.09 (0.42) 
Estradiol (pg/mL)3 ‐0.31 (0.07) ‐0.31 (0.13) ‐0.10 (0.51) ‐0.25 (0.04) 
Values are Spearman's rho (p-value); 1) n=84 controls ≥45; 2) n=31 controls <45, n=83 controls ≥45; 3) 
n=36 cases, 25 controls <45, n=45 cases, 72 controls ≥45     
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Table 4.7 Logistic regression analysis of the presence of CAC (Agatston score ≤0 vs. >0)   
 OR 95% CI p-value 
Model 1 Age (yrs) 1.05 1.00, 1.09 0.042 
PCOS (vs. Control) 2.26 1.39, 3.70 0.001 
Model 2a Age (yrs) 1.04 0.99, 1.09 0.127 
PCOS (vs. Control) 2.31 1.32, 4.06 0.003 
Complement C3 (per 10 mg/dL) 1.39 1.27, 1.52 <0.0001 
Model 2b Age (yrs) 1.06 1.00, 1.11 0.038 
PCOS (vs. Control) 1.82 1.01, 3.28 0.046 
Complement C3 (per 10 mg/dL) 1.26 1.14, 1.39 <0.0001 
Insulin Quartiles 1.86 1.37, 2.53 <0.0001 
Model 3 Age (yrs) 1.10 1.04, 1.16 0.002 
PCOS (vs. Control) 1.79 0.95, 3.37 0.072 
Complement C3 (per 10 mg/dL) 1.14 1.03, 1.27 0.011 
BMI (kg/m2) 1.25 1.17, 1.35 <0.0001 
Model 4 Age (yrs) 1.10 1.04, 1.17 0.001 
PCOS (vs. Control) 1.58 0.81, 3.05 0.176 
Complement C3 (per 10 mg/dL) 1.11 1.00, 1.24 0.057 
BMI (kg/m2) 1.23 1.14, 1.33 <0.0001 
Insulin Quartiles 1.29 0.90, 1.85 0.167 
Model 5 Age (yrs) 1.10 1.04, 1.17 0.001 
PCOS (vs. Control) 1.79 0.91, 3.53 0.092 
Complement C3 (per 10 mg/dL) 1.12 1.00, 1.25 0.049 
BMI (kg/m2) 1.22 1.13, 1.32 <0.0001 
Insulin Quartiles 1.30 0.90, 1.87 0.166 
African American (vs. White) 2.83 1.09, 7.34 0.033 
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Table 4.8 Ordinal regression analysis of CAC groups (Agatston score 0, 1-10, and ≥11) 
  OR 95% CI p-value 
Model 1 Age (yrs) 1.03 1.00, 1.06 0.058 
PCOS (vs. Control) 1.91 1.35, 2.71 0.0003 
Complement C3 (per 10 mg/dL) 1.21 1.15, 1.27 <0.0001 
Model 2a Age (yrs) 1.04 1.00, 1.07 0.027 
PCOS (vs. Control) 1.58 1.10, 2.26 0.013 
Complement C3 (per 10 mg/dL) 1.14 1.08, 1.20 <0.0001 
Insulin Quartiles 1.54 1.27, 1.89 <0.0001 
Model 2b Age (yrs) 1.04 1.00, 1.07 0.034 
PCOS (vs. Control) 1.57 1.09, 2.26 0.015 
Complement C3 (per 10 mg/dL) 1.09 1.03, 1.15 0.003 
BMI (kg/m2) 1.14 1.11, 1.18 <0.0001 
Model 3 Age (yrs) 1.04 1.01, 1.07 0.017 
PCOS (vs. Control) 1.46 1.00, 2.12 0.048 
Complement C3 (per 10 mg/dL) 1.06 1.00, 1.12 0.071 
BMI (kg/m2) 1.14 1.10, 1.18 <0.0001 
Insulin Quartiles 1.31 1.06, 1.62 0.012 
Model 4 Age (yrs) 1.04 1.01, 1.07 0.015 
PCOS (vs. Control) 1.68 1.13, 2.48 0.01 
Complement C3 (per 10 mg/dL) 1.06 0.99, 1.12 0.082 
BMI (kg/m2) 1.13 1.09, 1.17 <0.0001 
Insulin Quartiles 1.29 1.05, 1.60 0.017 
African American Race  
(vs. White) 1.73 1.09, 2.75 0.021 
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Table 4.10 Conditional logistic regression analysis of CAC (Agatston Score 0 vs. >0) among 
women with PCOS and controls (N=94) 
  B (S.E.) p-value OR (95% CI) 
Model 1 Case (vs. Control) 0.35 (0.22) 0.11 2.00 (0.86, 4.67) 
Model 2 Case (vs. Control) 0.38 (0.26) 0.14 2.14 (0.78, 5.83) 
Complement C3 
(per 10 mg/dL) 0.25 (0.12) 0.04 1.29 (1.01, 1.65) 
Model 3 Case (vs. Control) 0.16 (0.29) 0.31 1.38 (0.44, 4.35) 
Complement C3 
(per 10 mg/dL) 0.11 (0.01) 0.45 1.12 (0.84, 1.48) 
Insulin Quartiles 0.83 (0.42) 0.05 2.30 (1.00, 5.28) 
Model 4 Case (vs. Control) 0.22 (0.30) 0.47 1.54 (0.48, 4.94) 
Complement C3 
(per 10 mg/dL) 0.004 (0.18) 0.98 1.00 (0.71, 1.43) 
BMI (kg/m2) 0.21 (0.13) 0.09 1.24 (0.97, 1.59) 
47 original age-matched pairs, 24 discordant pairs (n=48 women); CI, 95% Wald Confidence 
Intervals 
 
 
Table 4.9 Frequency of CAC (Agatston Score 0 vs. > 0) in the 
matched pairs of women with PCOS and controls* 
Pairs (N=47) 
Controls 
No CAC (0) CAC  (1) 
Cases  
No CAC (0) 12 8 
CAC  (1) 16 11 
*47 original age-matched pairs (n=94 women), 24 discordant pairs 
(n=48 women) 
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5.0  TRAJECTORY ANALYSIS OF ABSOLUTE CHANGE IN BRACHIAL LUMEN 
DIAMETER AMONG WOMEN WITH POLYCYSTIC OVARY SYNDROME AND CONTROLS 
5.1 INTRODUCTION 
Flow-mediated dilation (FMD) is a w idely used non-invasive measure of endothelial 
function.  Endothelial dysfunction indicates early vascular injury and is a functional measure of 
subclinical atherosclerosis.1,2  Endothelial dysfunction has been s hown in animal models of 
atherogenesis,3 in individuals with atherosclerosis4,5 and in women with polycystic ovary 
syndrome (PCOS).6-9  PCOS is the most common reproductive endocrine disorder that affects 
6-10% of the women in the United States.10,11  Women with PCOS experience acne, excessive 
hair, weight gain and irregular periods.  Women with PCOS have an increase in cardiovascular 
disease (CVD) risk factors,7,12-15 and subclinical atherosclerosis as measured by coronary artery 
calcification16-19 and carotid artery intima-media thickness when compared to controls.2,20-26  
Studies have shown women with PCOS have lower FMD compared to controls,6-9 but some also 
have shown no differences.27,28  These contradicting results could be due to low sample sizes 
and the variability of the endothelial function test. 
The endothelial function test is difficult to measure and is prone to multiple sources of 
error or variance.  Endothelial function is assessed with B-mode ultrasound to measure changes 
in brachial artery diameter in response to an increase in sheer stress after transient ischemia.  
FMD is expressed as the percent change in lumen diameter (LD) from baseline in response to 
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increased flow after transient ischemia, and is calculated by taking the maximum LD divided by 
the baseline LD times 100.4  Lower FMD in response to an increased blood flow indicates 
endothelial dysfunction.  FMD is around 5% to 15% in most individuals, but lower or missing in 
individuals with cardiovascular disease.29   
Endothelial function is affected by many physiological and par ticipant factors, which 
increases the variability of FMD and decreases the power of a study to detect associations with 
FMD.  Low er endothelial dysfunction has been associated with age, BMI,30 hypertension,31,32 
inflammation,33,34  metabolic factors such as dyslipidemia and  insulin resistance,1,35,36 and 
psychosocial factors including stress,37 Bortner Type A behavior, Spielberger trait anger and 
Beck depression scores.38  In addition to these CVD risk factors, FMD varies with race,39 point in 
the menstrual cycle,40 with estrogens and menopausal status,41,42 and with alcohol43 and 
smoking.44  Endothelial function may also vary by the time of day, but this has not been 
consistently shown.45,46  Medications such as ACE inhibitors, statins, antioxidants, insulin 
sensitizers and L -arginine improve endothelial function.47,48  Endothelial function is also 
positively related to adiponectin, vitamin B and folic acid,49 exercise,47 tea,50 and cocoa.51  
Furthermore, factors that decrease brachial LD would intrinsically cause higher FMD levels 
because smaller vessels are able to dilate, or compensate for an i ncrease in blood flow and 
sheer stress, more than larger vessels.4  Also, the rate of the stimulus stress, which is believed 
to be an important determinant of the vascular response, varies across participants and could 
add to the variability of FMD.52   
Technical factors during the endothelial function assessment and differences in reading 
scans also contribute to the variability of FMD since the protocol for endothelial function is not 
standardized.  V ariations in the protocol include inflating blood pressure cuff up t o different 
pressures, occluding the vessel from 4 to 5 minutes and obtaining images at specific times.  
Bots et al. showed that the location and duration of occlusion increases FMD and could add to 
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the variability of FMD.53   FMD was higher in the upper arm versus lower arm, and the longer 
duration of occlusion was associated with a l arger FMD.  However, the investigators showed 
that technical factors have minimal contribution to the variability of FMD compared to traditional 
CVD risk factors.  
Taken together, these sources of variability make it difficult to interpret the data.  There 
are no guidelines for data management such as how to handle negative values and outliers.  To 
try to decrease the variability of FMD, investigators could take a new approach by using group-
based modeling to analyze the results from the endothelial function assessment.   
Semi-parametric group-based trajectory modeling, also called latent class growth 
modeling, is commonly used to model development and behavior in criminology and 
psychology.54  This method assumes there are subgroups in a popul ation that follow similar 
trajectories.  SAS Proc Traj models patterns of change in an outcome across multiple time 
points and identifies subgroups in the population.55,56  The advantage of this method is that the 
groups are not defined a priori, which differs from standard growth modeling.   
This method could identify and summarize subgroups of different patterns of absolute 
change in lumen diameter over the time course of the endothelial function test.  The analysis 
could identify participants who have a lower response and evaluate the associations between 
covariates and g roup membership.  This would improve the understanding of the endothelial 
test by removing the variability of FMD due to calculating the percent change in lumen diameter.  
It would also detect patterns of change, rather than an individual’s FMD value.   
For this analysis, it is assumed participants can be g rouped into different trajectories 
based on the change in LD after transient ischemia during the endothelial function test.  The aim 
of this paper was to determine whether there are distinct trajectories of absolute change in LD 
after transient ischemia among women with PCOS and controls, and whether PCOS status or 
other characteristics are associated with group trajectories. 
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5.2 METHODS 
5.2.1 Study Population 
This analysis is based from the Cardiovascular Health and Risk Measurement Study 
(CHARM) of women with PCOS and non-PCOS controls.  The investigators, Talbott and Sutton-
Tyrrell,  described the methodology and recruitment of the original study previously.57  Briefly, 
they identified women aged 19-55 diagnosed with PCOS between 1970 and 1993 t hrough 
medical records in the Division of Reproductive Endocrinology at Magee-Women’s Hospital 
(Pittsburgh, PA), and recruited women through private practices and t he local chapter of the 
PCOSA support group.  The University of Pittsburgh institutional review board approved the 
protocols, and al l participants gave consent before enrolling.  Investigators obtained a c linical 
diagnosis of PCOS at baseline, defined by the NIH as a history of anovulation and ei ther (1) 
clinical evidence of androgen excess (hirsutism) or an elevated testosterone level (0.2 nmol/L) 
or (2) a luteinizing hormone/follicle-stimulating hormone ratio (LH/FSH) greater than 2.0.  
Investigators matched PCOS cases to controls by age (±5 years) and race.  The neighborhood 
controls came from voter’s registration tapes and Cole’s Cross Reference Directory of 
Households from 1993.   
The present study was based from the second follow-up of CHARM that occurred during 
1997 to 1999 where 335 women 30-60 years old were contacted to assess measures of 
subclinical cardiovascular disease.  This present analysis included 128 women with PCOS and 
148 controls that underwent the endothelial function ultrasound assessment during the 1997 to 
1999 follow-up visit (Figure 5.1). 
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5.2.2 Covariates 
The clinical assessments for participant characteristics have been previously 
described.20,57,58  Briefly, investigators collected height, weight, BMI, waist and hi p 
circumference (cm), waist to hip ratio, blood pressure, and serum concentrations of hormones, 
total cholesterol, LDLc, HDLc, triglycerides, fasting glucose and insulin, C-reactive protein and 
hormones that included sex hormone binding globulin (SHBG), luteinizing hormone (LH), follicle 
stimulating hormone (FSH), total testosterone, progesterone and estradiol.  Participants 
completed a questionnaire on medical, surgical, menstrual and reproductive history, medication 
use, lifestyle, and family history of PCOS.  For this analysis, the quantitative insulin sensitivity 
check index (QUICKI) was calculated (QUICKI= 1/[log fasting insulin concentration (µU/mL) + 
log glucose concentration (mg/dL)]).59  QUICKI is a measure of insulin sensitivity where lower 
values indicate insulin resistance. 
5.2.3 Endothelial Function Assessment 
Flow-mediated dilation was measured by Toshiba SSA-270A and Hewlett Packard 5500 
duplex scanners.  Technicians placed a cuff on the right forearm and an ultrasound probe two 
inches above the antecubital fossa.  The procedure began after the patients rested for ten 
minutes.  The sonographer recorded a one minute baseline digital and then inflated the cuff to 
50 mmHg above the systolic blood pressure for four minutes to induce hyperemia.  The 
sonographer recorded digital images post deflation every thirty seconds for two minutes.  The 
sonographer measured the brachial LD from digital images timed to end diastole of the cardiac 
cycle.  Three measurements of the LD for each time point were averaged. 
 93 
 
5.2.4 Statistical Methods 
Data preparation 
To prepare the data, variables were created that represented the 30 second time 
variable and the corresponding absolute change in LD (time 0 and rchg0, time 1 and rchg1, 
etc.).  The absolute change in LD at time zero was set to zero for all participants.  The censored 
normal distribution model was in SAS Proc Traj was used, which was developed by Nagin and 
colleagues to model group trajectories.  The single outcome was absolute change in LD at the 
30 second time points.  
 
Model Selection and Diagnostics 
The optimal number of groups was determined for up to 5 groups using second order 
polynomial models by evaluating model fits using the BIC criteria and the estimated log Bayes 
factor (Table 5.1).  For this data, a three-group trajectory model was identified as the optimal 
number of groups.  Some group sizes were less than five percent for models exceeding three 
groups.  Once the three group model was determined to be the optimal model, the cubic term 
was added to each group.  Non-significant terms were removed from each group and models 
were evaluated using the BIC criteria.   
To check models, trajectories were graphed with the 95% confidence intervals, and the 
average posterior probabilities of membership in each group (AvePP) and the odds of correct 
classification (OCC)2  were calculated (Table 5.2).54  The OCC was calculated by:  
OCCj=[(AvePPj/1-AvePPj)/(πj/1- πj)]; where πj  is the estimated probability of group membership.  
More accurate group assignments correspond to a larger OCC.  Adequate models should have 
an AvePP of >0.70 and an OCC of >5. 
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Characteristics by Group 
Posterior probabilities were used to classify participants into groups.  Descriptive 
statistics were computed for categorical and continuous variables by groups.  Differences in 
levels of characteristics across groups were evaluated using ANOVA for normally distributed 
variables, the Welsh test for normally distributed variables with unequal variances across 
groups, the Kruskal-Wallis Test for non-normally distributed variables, and the Chi-square or 
Fisher’s exact tests for categorical variables.  Women using hormone replacement therapy or 
oral contraceptives were excluded when analyzing hormone levels so the results were not 
influenced by hormone use.     
Group membership was modeled using multinomial logistic regression analyses to 
identify possible characteristics associated with trajectories.  The multinomial model evaluated 
differences in variables between non-dilators and enhanced dilators compared to the dilators as 
the reference.  Group two was selected as the reference group because it contained the largest 
number of women and was hypothesized to represent the endothelial response for a general 
population.  Non-normal variables were transformed and the log of insulin and glucose were 
divided by the standard deviation for ease of interpreting model parameters.  The variables were 
modeled adjusting for baseline lumen diameter, a major component of the response of the 
change in lumen diameter.  Variables with a p-value <0.20 were assessed in multivariable 
models using forward stepwise selection.  All first order interactions with PCOS status were 
evaluated.  Boxplots were created for the significant variables to illustrate differences by group.  
SAS (release 9.2; SAS, Cary, NC) was used for the trajectory modeling and all other analyses 
were done with PASW (version 18; IBM SPSS Inc., Chicago, IL). 
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5.3 RESULTS 
The analysis identified three distinct patterns of absolute change in LD, which were 
labeled as enhanced dilators, dilators, non-dilators (Figure 5.2).  There were 117 (42.4%) 
women classified as non-dilators, 123 (44.6%) women classified as dilators and 36 (13%) 
women classified as enhanced dilators.   
When descriptive characteristics were compared across groups, insulin levels were 
significantly different between non-dilators, dilators and enhanced dilators, p=0.03 (Table 5.3).  
The other descriptive characteristics were not significantly different across groups.  S imilarly, 
the hormone, inflammatory, fibrinolytic and coagulation factors were not different across the 
groups (Tables 5.4 and 5.5).  However, significant differences were seen in endothelial function 
parameters that included baseline lumen diameter, maximum change in lumen diameter, 
absolute change in lumen diameter, and FMD (Table 5.6).   
The distribution of women with PCOS was not different across groups as there were 
42.7% of the non-dilators were women with PCOS, 46.3% of the dilators were women with 
PCOS, and 58.3% of the enhanced dilators were women with PCOS, p=0.26 (Table 5.7).  The 
other categorical variables were not different by group.  When stratified by women with PCOS 
and controls, the selected factors were also not significantly different across groups (Table 5.8).  
There were borderline significant differences across groups with respect to insulin and glucose 
among the controls. 
In the multinomial logistic regression analysis, larger baseline lumen diameter was 
associated with a 2 .05 greater likelihood of non-dilators compared to dilators (95% CI [1.09, 
3.87], p=0.03) (Table 5.9).  After adjusting for PCOS, age and baseline lumen diameter, lower 
insulin was associated with a greater likelihood of non-dilators compared to dilators (OR 0.70, 
95% CI [0.52, 0.93], p=0.02), and higher HDLc was borderline significantly associated with a 
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greater likelihood of non-dilators compared to dilators (OR=1.02, 95% CI [1.00, 1.04], p=0.05).  
Boxplots of these variables also illustrated these associations with group membership (Figures 
5.3 thru 5.5).  There was a significant interaction term with cholesterol quartiles and case control 
status for the non-dilators compared to dilators (OR 0.55, 95% CI [0.34, 0.90], p=0.02) after 
adjusting for age, baseline lumen diameter and insulin quartiles.  The graph of the predicted 
probabilities of the non-dilators from the interaction model by case control status showed that as 
cholesterol quartiles increases, the probability of non-dilators versus dilators decreases for 
cases and increases for controls (Figure 5.6).  This suggests that higher cholesterol is 
associated with a greater likelihood of being a dilator in cases, but being a non -dilator in 
controls.  There was no evidence of other interactions with case control status.  The results of 
all the descriptive and regression analyses did not change when excluding women on 
medications for insulin and glucose. 
5.4 DISCUSSION 
This analysis identified three distinct patterns of absolute change in lumen diameter 
during the time course of the endothelial function test.  Most of the women were classified as 
non-dilators and dilators, 35.2% and 4 6.1%, respectfully, whereas 13.0% were classified as 
enhanced dilators.  The results are surprising because it suggests 35.2% of the women have 
evidence of a l ow endothelial response indicative of endothelial dysfunction.  I nsulin and t he 
endothelial function parameters were the only variables that were different across groups.  The 
proportion of women with PCOS did not differ between groups.  Factors associated with the 
non-dilators compared to the dilators included higher baseline lumen diameter after adjusting for 
case control status and age, and lower insulin and higher HDLc after adjusting for case control 
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status, age and baseline lumen diameter.  There was a significant interaction between total 
cholesterol and P COS status in which increasing cholesterol quartiles were associated with 
non-dilators in controls but associated with dilators in cases.    
 This analysis showed that a larger baseline diameter was associated with non-dilators 
compared to dilators (3.04±0.41 versus 2.92±0.43, p=0.03, respectively).  T hese findings fall 
within the range of reported baseline LDs of 2 to 7 mm,60 and are similar to studies that showed 
a negative association of FMD with baseline LD.60-62  As expected, women in the non-dilator 
group had significantly lower absolute change in lumen diameter compared to dilators 
(0.08±0.08 versus 0.22±0.06, p<0.0001) and t he enhanced dilators had s ignificantly higher 
absolute change compared to dilators (0.40±0.08 versus 0.22±0.06, p<0.0001).  The absolute 
change in LD has been shown to range from -0.07 to 0.71 mm.60  In women, the mean absolute 
change has been shown to be anywhere from 0.43±0.02 mm,63 0.27±0.13 mm62 to 0.139±0.002 
mm.39  Increases in LD are a normal process of arterial remodeling that occurs in response to 
changes in blood flow to preserve vascular tone and sheer stress.64  However, larger baseline 
diameters have less ability to respond to increases in blood flow.4  A larger baseline LD has 
been associated with lower endothelial function,65,66 coronary artery calcium,67 and coronary 
artery disease5,65 and a smaller absolute change has been associated with peripheral arterial 
disease.68   
Besides baseline LD, the other strongest determinant of the non-dilators was insulin in 
which lower insulin levels were associated with non-dilators compared to dilators.  I nsulin is 
involved in vasodilation,69-74 and affects NO synthesis74 This might seem counterintuitive given 
that insulin is involved in vasoconstriction,75 and insulin resistance6 and diabetes35,48 are 
associated with lower FMD.  H owever, insulin resistance blunts the vasodilating signaling of 
insulin, whereas the vasoconstricting signaling is unchanged.75  This could explain why lower 
insulin was associated with non-dilators.   
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An unexpected finding was that higher HDLc was associated with non-dilators compared 
to dilators.  However, this was borderline significant at p=0.05.  Evidence suggests that under 
certain conditions, the beneficial actions of HDLc are lost and can become a pro-inflammatory 
factor (piHDLc).  Levels of piHDLc have been shown to be higher in inflammatory states, such 
as in women with systemic lupus erythematosus (SLE),76 and associated with carotid intima-
media thickness in women with SLE.77  The function of HDLc was independent of HDLc serum 
levels in these studies, but suggests a potential mechanism for the association of higher HDLc 
and non-dilators. 
There was a significant interaction between cholesterol and PCOS status in which higher 
cholesterol quartiles were associated with non-dilators among the controls, but associated with 
dilators among the cases.  S tudies have shown higher total cholesterol is associated with 
reduced endothelial function.78  However, total cholesterol has not been associated with FMD in 
women with PCOS and controls (spearman correlation r=0.045, p=0.71).6  A study among 
women with PCOS showed that the duration of reactive hyperemia (durRH), defined as the time 
for the blood flow to return to baseline levels after reactive hyperemia, was shorter in women 
with PCOS versus controls (63.75±13.33 seconds versus 113.18±20.92 seconds, p=0.036).79  
The investigators showed that total cholesterol was not significantly related to the durRH, but 
the spearman correlations were in opposite directions between cases (r=-0.17, p=0.49) and 
controls (r=0.14, p=0.68).  Thus, the interaction between case control status and group 
membership could reflect differences between women with PCOS and c ontrols in how 
cholesterol affects stimulus stress or other mechanisms of the endothelial response after 
reactive hyperemia.   
Underlying explanations for these findings are that these factors could affect important 
regulators of vascular function such as nitric oxide (NO) function74 and oxidative stress.  In 
addition, differences in stimulus stress could explain the results.  S timulus stress is a m ajor 
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determinant of FMD along with baseline LD,80,81 but not always measured in conjunction with 
endothelial function.  Recently researchers recommend that the dilation should be corrected for 
the rate of stimulus stress achieved during hyperemia, as this varies across participants and 
could account for variations in FMD.80,82  However, correcting for the stimulus stress is under 
debate because there might not be an association between sheer stress and FMD in certain 
populations and study designs,83 or the association may not be linear.84   
Many published guidelines recommend studies to report baseline LD, absolute change 
in LD and FMD, area under the curve (AUC) and time to maximum diameter.56   This would help 
to interpret the results from the endothelial function assessment and reduce variability across 
studies.  In addition, investigators have tried to decrease the variability and increase sensitivity 
of the endothelial function data by using various analytic methods.  I nvestigators have used 
AUC85 as an alternative to FMD and shown it is more sensitive in detecting endothelial 
responses over the time course of the measurement than FMD.60  However, this assumes 
investigators have continuous accurate measures of LD over the time course.  This is not easy 
to obtain because of the technical precision that it entails.  Also, some studies measure LD at 
specific time points rather than continuously.  Other investigators have looked at the time 
course86 and used it to classify responders based on the AUC of FMD.61   
These methods are similar to this trajectory analysis because the participant endothelial 
responses were classified into groups.  This analysis also allowed for the adjustment for 
baseline LD when analyzing the absolute change, which is not recommended when analyzing 
FMD because baseline LD is part of the calculation.  Another benefit of this analysis was that 
the absolute change has been shown to be more consistent than FMD with changing baseline 
LDs.60   
A limitation of this study was that the LD was measured at 30 second intervals.  This 
might have underestimated the true maximum diameter, but may have a small impact on the 
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results because the focus was on patterns of change rather than the maximum dilation.  Another 
limitation was that endothelium-independent dilation was not measured so the function of the 
smooth muscle cells on the endothelial response could not be evaluated.  Also, stimulus stress 
was not measured, which has been suggested to be as important as baseline LD in determining 
the endothelial response to sheer stress.80,82  However, this limitation exists in most studies 
because sheer stress is rarely assessed and a djusting for the stimulus stress is still under 
debate. 
Despite these limitations, this trajectory analysis identified individuals with similar 
patterns of absolute change in LD and identified factors associated with group membership.  It 
would be important to replicate this method in different populations while taking into account the 
aforementioned variability in the endothelial response due to baseline LD and stimulus stress.  
Larger studies may be needed to increase the power of this analysis to identify factors 
associated with group membership.  Future studies could look longitudinally and see if 
individuals fall into the same trajectory group over time.  Studies could also evaluate the effect 
changes in CVD risk factors have on group membership.   
In summary, baseline lumen diameter, insulin and HDLc were identified as important 
factors in the endothelial response after reactive hyperemia.  There was also evidence that the 
association of total cholesterol and group membership was different between women with 
PCOS and  controls.  Clearly much remains to be  known about the mechanisms of 
vasoreactivity.  Endothelial function is a complex process; many factors play a role and it varies 
under different conditions.  Thus, multiple methods should be used to analyze and interpret the 
results from the endothelial function assessment.  Applying this analytic method to past and 
future studies of endothelial function will allow researchers to evaluate the utility of this method 
as it could be a less variable way to analyze endothelial data compared to current methods.  In 
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conclusion, this analysis showed promise to be an additional tool to understand factors affecting 
endothelial function and identify individuals with endothelial dysfunction. 
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5.6 TABLES AND FIGURES FOR CHAPTER FOUR 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Case and control selection 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 Model selection based on the log Bayes factor 
No. of Groups BIC (N=128) 2(ΔBIC)≈2loge(B10) 
1 1237.47 
 2 1586.9 698.86 
3 1684.06 194.32 
4 1741.41 114.7 
5 1759.33 35.84 
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Figure 5.2 Absolute change in lumen diameter after reactive hyperemia 
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Table 5.2 Diagnostics for the three group model  
Group AvePP 
Estimated Group Membership 
Probabilities (πj) OCC 
Non-Dilators 0.95 0.43 25.69 
Dilators 0.93 0.44 16.99 
Enhanced Dilators 0.98 0.14 311.09 
Average Group Probabilities (AvePP); Odds of Correct Classification (OCC) 
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Table 5.3 Descriptive variables for women with PCOS and controls aged 30-60 from CHARM II endothelial function test by group 
  N All n Non-Dilators n Dilators n Enhanced Dilators 
p-
value 
Age (yr) 276 42.55±7.02 117 42.50±7.24 123 42.72±6.86 36 42.13±7.03 0.90 
Weight (lbs.)  276 172.93±44.50 117 169.77±42.32 123 175.12±49.15 36 175.71±33.79 0.57ǂ  
Waist Circumference (cm) 264 87.48±16.49 109 86.44±16.82 120 87.71±17.19 35 89.89±12.68 0.55 
Waist-to-hip ratio 263 0.80±0.07 109 0.79±0.08 119 0.80±0.07 35 0.81±0.06 0.25ǂ  
BMI (Kg/m2)  276 29.21±7.21 117 28.54±6.81 123 29.66±7.88 36 29.82±5.94 0.42 
SBP (mm Hg) 276 114.64±14.86 117 115.57±16.02 123 114.36±14.65 36 112.61±11.38 0.56 
DBP (mm Hg) 276 74.27±9.10 117 74.75±9.02 123 73.82±9.10 36 74.25±9.56 0.73 
Insulin (µU/mL)* 275 12.90 (9.60, 18.50) 116 
12.00 
(9.20, 16.73) 123 
13.20 
(9.70, 20.70) 36 
14.95 
(11.03, 23.05) 0.03* 
Glucose (mg/dL)* 272 90.05 (83.92, 97.07) 116 
91.37 
(84.79, 97.73) 121 
89.18 
(82.16, 97.07) 35 
87.42 
(82.16, 94.44) 0.25* 
QUICKI 272 0.32±0.03 116 0.33±0.02 121 0.32±0.03 35 0.32±0.02 0.17 
Triglycerides (mg/dL)*  276 110.00 (75.00, 156.00) 117 
103.50 
(70.25, 141.25) 123 
110.00 
(77.00, 163.00) 36 
137.50 
(89.00, 163.00) 0.15 
Total Cholesterol (mg/dL)  276 205.34±35.62 117 204.28±35.23 123 205.20±35.63 36 209.22±37.54 0.77 
HDLc (mg/dL)  276 56.83±15.20 117 58.69±15.57 123 56.18±15.39 36 53.07±12.64 0.12 
LDLc (mg/dL)  273 123.05±32.61 114 121.39±30.20 123 123.07±32.63 36 128.21±39.62 0.55 
Leptin (ng/mL)*  238 19.10 (11.60, 31.13) 93 
18.60 
(10.05, 32.15) 113 
19.00 
(11.70, 32.30) 32 
19.65 
(13.30, 28.03) 0.91* 
Values are the mean±SD or *median (Inter-Quartile Range: 25th, 75th percentile); p-value by ANOVA or ǂWelsh test or *Kruskal-Wallis 
Test; excluding women on insulin meds (n=7) or excluding women on hypoglycemic meds (n=9) did not change results 
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Table 5.4 Hormone variables by group (excluding women currently using OCs or HRTs) 
  N All n Non-Dilators n Dilators n Enhanced Dilators p-value 
Age (yr) 146 41.49±6.19 58 41.46±6.37 67 41.60±5.85 21 41.26±7.01 0.98 
BMI (Kg/m2) 146 30.85±7.57 58 29.98±7.77 67 31.22±7.94 21 32.03±5.61 0.49 
Sex Hormone Binding 
Globulin (nmol) 146 175.81±91.42 58 195.19±94.62 67 166.02±87.02 21 153.50±90.27 0.10 
Free Testosterone 
(nmol/L)* 144 
1.57 
(0.93, 2.46) 58 
1.39 
(0.79, 2.45) 66 
1.46 
(1.02, 2.44) 20 
1.95 
(1.46, 2.95) 0.14* 
Total Testosterone 
(ng/dL)* 146 
36.52 
(24.07, 56.66) 58 
35.18 
(23.78, 54.50) 67 
37.27 
(22.34, 59.69) 21 
37.21 
(29.28, 49.43) 0.94 
Luteinizing hormone 
(miU/mL)* 123 
5.27 
(2.29, 10.52) 45 
5.75 
(2.76, 9.28) 58 
5.37 
(2.63, 10.77) 20 
2.94 
(1.68, 11.45) 0.56 
Estradiol (pg/mL)* 117 70.60 (46.20, 106.95) 45 
73.90 
(41.45, 110.75) 52 
71.10 
(41.68, 112.18) 20 
64.90 
(51.13, 96.38) 0.38 
Estrone (pg/mL)* 117 45.70 (26.50, 60.50) 45 
45.30 
(25.95, 60.75) 52 
45.80 
(28.60, 60.58) 20 
43.30 
(22.33, 62.70) 0.47 
Free estradiol index 
(estradiol/SHBG)* 96 
0.47 
(0.26, 0.83) 37 
0.65 
(0.22, 0.85) 42 
0.55 
(0.30, 0.85) 17 
0.43 
(0.24, 0.99) 0.96 
Values are the mean±SD or *median(Inter-Quartile Range: 25th, 75th percentile); p-value by ANOVA or *Kruskal-Wallis Test 
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Table 5.5 Inflammatory, fibrinolytic and coagulation factors by group 
  N All n Non-Dilators n Dilators n Enhanced Dilators p-value 
PAI-1 (ng/mL)  270 18.91 (9.95, 36.00) 114 
17.62 
(10.15, 33.69) 121 
21.00 
(9.00, 38.95) 35 
19.39 
(9.00, 31.00) 0.71 
CRP (mg/dL)   272 1.75 (0.97, 3.34) 115 
1.64 
(0.90, 3.27) 122 
1.65 
(0.98, 3.70) 35 
2.16 
(1.13, 2.85) 0.73 
Factor VIIc (%)  270 125.50 (110.00, 149.25) 114 
124.00 
(105.50, 149.00) 121 
127.00 
(116.00, 150.50) 35 
125.00 
(112.00, 159.00) 0.39 
D_Dimer (ng/mL)  272 91.04 (61.31, 144.87) 115 
91.67 
(60.24, 150.08) 122 
98.16 
(60.80, 136.69) 35 
85.37 
(69.58, 145.23) 0.99 
Fragment 1.2 (nM)  272 1.05 (0.88, 1.32) 115 
1.07 
(0.89, 1.22) 122 
1.02 
(0.83, 1.36) 35 
1.07 
(0.92, 1.40) 0.72 
Values are the median (Inter-Quartile Range: 25th, 75th percentile), p-value by Kruskal-Wallis Test 
 
Table 5.6 Endothelial function parameters by group 
  N All n Non-Dilators n Dilators n Enhanced Dilators p-value 
Baseline Lumen Diameter (mm) 276 2.98±0.43 117 3.04±0.41 123 2.92±0.43 36 3.06±0.48 0.05 
Maximum Change in Lumen 
Diameter (mm) 276 3.17±0.45 117 3.12±0.41 123 3.14±0.44 36 3.46±0.47 0.0001 
Absolute Change in Lumen 
Diameter (mm) 276 0.19±0.13 117 0.08±0.08 123 0.22±0.06 36 0.40±0.08 <0.0001 
FMD (%) 276 6.41±4.56 117 2.77±2.80 123 7.80±2.41 36 13.50±3.76 <0.0001ǂ  
Values are the mean±SD, p-value by ANOVA or ǂWelch test 
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Table 5.7 Selected categorical factors by group 
  
All N (%) 
Non-
Dilators 
n (%) 
Dilators 
n (%) 
Enhanced 
Dilators 
n (%) 
p-value 
PCOS 128 (46.4) 50 (42.7) 57 (46.3) 21 (58.3) 0.26 
African American Race 41 (14.9) 20 (17.1) 16 (13.0) 5 (13.9) 0.66 
Age ≥45 years old 96 (34.8) 45 (38.5) 38 (30.9) 13 (36.1) 0.46 
Education-Highest grade 
completed      
 10-12  68 (24.6) 30 (25.6) 29 (23.6) 9 (25.0) 0.93 
 13-16 150 (54.3) 60 (51.3) 70 (56.9) 20 (55.6)  
 17 58 (21.0) 27 (23.1) 24 (19.5) 7 (19.4)  
Current Smoker 50 (18.1) 18 (15.4) 22 (17.9) 10 (27.8) 0.24 
OC user  39 (14.1) 17 (14.5) 15 (12.2) 7 (19.4) 0.54 
HRT user  37 (13.4) 16 (13.7) 18 (14.6) 3 (8.3) 0.67* 
Hysterectomy  19 (6.9) 9 (7.7) 7 (5.7) 3 (8.3) 0.76* 
Never been pregnant  73 (26.4) 31 (26.5) 32 (26.0) 10 (27.8) 0.98 
Postmenopausal  
(no period in last 12 months)  57 (20.7) 27 (23.1) 25 (20.3) 5 (13.9) 0.49 
Obesity      
 
Normal and  
Overweight (<30) 164 (59.4) 72 (61.5) 72 (58.5) 20 (55.6) 0.79 
 BMI Class 1, 2, 3 (≥30) 112 (40.6) 45 (38.5) 51 (41.5) 16 (44.4)  
High blood pressure doctor 
diagnosed 34 (12.3) 18 (15.4) 14 (11.4) 2 (5.6) 0.31* 
Type 2 Diabetes 
 doctor diagnosed, or  
glucose ≥126 mg/dL 
20 (7.2) 9 (7.7) 10 (8.1) 1 (2.8) 0.65* 
Hypertriglyceridemia  
≥150 mg/dL1 78 (28.3) 28 (24.1) 35 (28.5) 15 (41.7) 0.13 
Values are number (percent within group); p-value by Pearson Chi-Square or *Fisher’s Exact 
Tests; NA= Not available; 1) n=116 non-dilators 
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Table 5.8 Selected factors in women with PCOS and controls by group 
    Women with PCOS Controls 
  Group 1 (n=50) n (%) 
Group 2  (n=57) 
n (%) 
Group 3 (n=21) 
n (%) p-value 
Group 1 (n=67) 
n (%) 
Group 2 (n=66) 
n (%) 
Group 3 (n=15) 
n (%) p-value 
Age (yrs) 40.77±6.92 42.75±7.30 39.98±6.50 0.19 43.79±7.26 42.68±6.52 45.13±6.83 0.40 
BMI (Kg/m2) 30.25±7.70 30.94±8.59 31.39±6.27 0.83 27.27±5.80 28.56±7.09 27.63±4.82 0.50 
Insulin (μU/mL)1 14.05 16.20 14.70 0.59  11.20 11.60 15.40 0.05 
(9.65, 22.55) (10.10, 21.90) (10.40, 25.20) (9.18, 14.25) (9.35, 17.28) (12.30, 18.20) 
Glucose (mg/dL)2 89.62  (84.57, 95.97) 
91.81  
(83.92, 99.70) 
87.42  
(81.28, 94.44) 0.31 
91.81  
(85.45, 98.17) 
87.42  
(82.16, 92.90) 
90.05  
(82.16, 101.24) 0.06 
QUICKI 0.32±0.03 0.32±0.03 0.32±0.02 0.61 0.33±0.02 0.33±0.03 0.32±0.02 0.14 
African American Race 7 (14.0) 9 (15.8) 3 (14.3) 1.0* 13 (19.4) 7 (10.6) 2 (13.3) 0.39* 
Age ≥45 years old 15 (30.0) 17 (29.8) 6 (28.6) 0.99 30 (44.8) 21 (31.8) 7 (46.7) 0.26 
Current Smoker  8 (16.0) 9 (15.8) 6 (28.6) 0.39* 10 (14.9) 13 (19.7) 4 (26.7) 0.43* 
OC user  10 (20.0) 6 (10.5) 4 (19.0) 0.36* 7 (10.4) 9 (13.6) 3 (20.0) 0.52* 
HRT user  7 (14.0) 9 (15.8) 1 (4.8) 0.48* 9 (13.4) 9 (13.6) 2 (13.3) 1.0* 
Hysterectomy  4 (8.0) 3 (5.3) 1 (4.8) 0.89* 5 (7.5) 4 (6.1) 2 (13.3) 0.59* 
Never been pregnant 
 19 (38.0) 16 (28.1) 7 (33.3) 0.55 12 (17.9) 16 (24.2) 3 (20.0) 0.62* 
Postmenopausal  
(not had at least 1 period 
last 12 months)  
7 (14.0) 11 (19.3) 1 (4.8) 0.28* 20 (29.9) 14 (21.2) 4 (26.7) 0.52* 
Obesity (BMI ≥30) 26 (52.0) 27 (47.4) 12 (57.1)  0.73 19 (28.4) 24 (36.4) 4 (26.7) 0.58* 
High Blood Pressure 
(doctor diagnosed) 11 (22.0) 12 (21.1) 1 (4.8) 0.20* 7 (10.4) 2 (3.0) 1 (6.7) 0.22* 
NIDDM (doctor 
diagnosed) 6 (12.0) 8 (14.0) 0 (0) 0.21* 0 (0) 1 (1.5) 0 (0) 0.55* 
NIDDM or Glucose ≥126  
mg/dL 8 (16.0) 8 (14.0) 1 (4.8) 0.45* 1 (1.5) 2 (3.1) 0 (0) 0.72* 
Values are number (percent within group); p-value by Pearson Chi-Square or *Fisher's exact test; NA= Not available; excluding women on insulin meds (n=7) or 
women on hypoglycemic meds (n=9) did not change results; 1) controls group 1 n=66; 2) PCOS group 2 n=55, controls group 1 n=66 and controls group 3 n=14 
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Table 5.9 Multinomial logistic regression analysis using the dilator group as the reference 
Model Group Odds Ratio (95% CI) p-value 
1 Non-Dilators PCOS (vs. Control) 0.80 (0.48, 1.35) 0.41 
Age (years) 1.00 (0.96, 1.04) 0.91 
Baseline Lumen Diameter (mm) 2.05 (1.09, 3.87) 0.03 
Enhanced 
Dilators 
PCOS (vs. Control) 1.50 (0.70, 3.23) 0.30 
Age (years) 1.00 (0.94, 1.05) 0.89 
Baseline Lumen Diameter (mm) 2.10 (0.87, 5.05) 0.10 
2 Non-Dilators PCOS (vs. Control) 0.92 (0.54, 1.58) 0.76 
Age (years) 0.99 (0.96, 1.03) 0.72 
Baseline Lumen Diameter (mm) 2.51 (1.29, 4.89) 0.007 
Insulin  
(per standard deviation of the log) 0.70 (0.52, 0.93) 0.02 
Enhanced 
Dilators 
PCOS (vs. Control) 1.48 (0.68, 3.23) 0.33 
Age (years) 1.00 (0.95, 1.05) 0.93 
Baseline Lumen Diameter (mm) 2.10 (0.84, 5.27) 0.11 
Insulin  
(per standard deviation of the log) 1.04 (0.71, 1.51) 0.86 
3 Non-Dilators PCOS (vs. Control) 0.84 (0.49, 1.42) 0.50 
Age (years) 0.99 (0.96, 1.03) 0.71 
Baseline Lumen Diameter (mm) 2.44 (1.25, 4.75) 0.009 
HDLc (mg/dL) 1.02 (1.00, 1.04) 0.05 
Enhanced 
Dilators 
PCOS (vs. Control) 1.48 (0.69, 3.19) 0.32 
Age (years) 1.00 (0.95, 1.06) 0.96 
Baseline Lumen Diameter (mm) 1.97 (0.78, 5.03) 0.15 
HDLc (mg/dL) 0.99 (0.97, 1.02) 0.61 
4 Non-Dilators PCOS (vs. Control) 4.00 (1.08, 14.91) 0.04 
Age (years) 0.99 (0.96, 1.04) 0.78 
Baseline Lumen Diameter (mm) 2.70 (1.37, 5.32) 0.004 
Insulin  
(per standard deviation of the log) 0.72 (0.54, 0.98) 0.04 
Cholesterol Quartiles  1.23 (0.90, 1.69) 0.20 
PCOS*Cholesterol Quartiles 0.55 (0.34, 0.90) 0.02 
Enhanced 
Dilators 
PCOS (vs. Control) 6.79 (0.97, 47.63) 0.05 
Age (years) 1.00 (0.94, 1.06) 0.91 
Baseline Lumen Diameter (mm) 2.25 (0.89, 5.66) 0.09 
Insulin  
(per standard deviation of the log) 1.07 (0.72, 1.58) 0.74 
Cholesterol Quartiles 1.37 (0.83, 2.27) 0.22 
PCOS*Cholesterol Quartiles 0.55 (0.27, 1.10) 0.09 
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Figure 5.3 Boxplot of baseline brachial lumen diameter by group 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Boxplot of insulin by group 
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Figure 5.5 Boxplot of HDL-c by group 
 
Figure 5.6 Graph of the predicted probabilities of non-dilators compared to dilators from the 
multinomial logistic regression model with the case control and cholesterol interaction 
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6.0  GENERAL DISCUSSION 
6.1 SUMMARY OF FINDINGS 
Below is a s ummary of this dissertation on markers for subclinical cardiovascular 
disease in women with PCOS and c ontrols.  Each chapter evaluated a different measure of 
subclinical atherosclerosis that included CIMT, CAC and endothelial function. 
Chapter three summarized and evaluated the literature on CIMT in women with PCOS 
compared to controls.  The first meta-analysis on s ubclinical atherosclerosis in women with 
PCOS indicated women with PCOS had greater CIMT when compared to controls.  The 
summary estimate of the mean difference in CIMT between women with PCOS and controls is 
comparable to a seven year progression in CIMT.  There was significant heterogeneity across 
studies that may be due to that fact that PCOS is a common complex heterogeneous syndrome.  
This analysis also revealed that the pattern of CIMT estimates were more constant across 
studies with the highest quality assessment of CIMT.  This highlights the importance using 
standardized ultrasound protocols and reporting detailed methods as it may explain part of the 
inconsistencies of the literature.  
Chapter four included the first study of the association between complement protein C3, 
CVD risk factors and subclinical CVD in middle-aged women with PCOS and their respective 
controls.  Although not significant, women with PCOS had higher C3 levels when compared to 
controls, which was more evident in women ≥45 years old.  C3 significantly correlated with 
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traditional CVD risk factors regardless of age group or case control status.  Higher circulating 
C3 levels were associated with the presence of CAC and with increasing CAC groups after 
adjusting for case control status and age, and either insulin or BMI.  In the fully adjusted model 
with the aforementioned factors and African American race, C3 was significantly associated with 
the presence of CAC.  The association between C3 and CAC was attenuated when adjusting for 
insulin and B MI, but was expected since adiposity and  insulin resistance are sources of 
complement and other pro-inflammatory factors.  The results indicated that serum C3 is 
associated with subclinical cardiovascular disease and may be a specific atherosclerotic 
inflammatory marker in women with and without PCOS. 
In chapter five, a novel trajectory analysis was used to analyze the endothelial function 
data from CHARM.  The trajectory analysis identified three distinct patterns of absolute change 
in lumen diameter during the endothelial function test that were labeled as non-dilators, dilators 
and enhanced dilators.  Most of the women were classified as non-dilators and di lators.  
Baseline lumen diameter, insulin and HDLc were associated with group membership, and an 
interactive effect between PCOS status and total cholesterol on group membership was 
detected.  Clearly much remains to be known about the mechanisms of endothelial function.  
Endothelial function is complex and many factors play a  role, which varies under different 
conditions.  Thus, multiple methods should be used to analyze and interpret the results from the 
endothelial function assessment.  This analysis showed promise to be an add itional tool to 
understand factors affecting endothelial function and  identify individuals with endothelial 
dysfunction. 
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6.2 PUBLIC HEALTH SIGNIFICANCE  
PCOS is a  common reproductive endocrine disorder with short and long term 
complications for women.  Young women might be c oncerned with cosmetic or reproductive 
symptoms of PCOS such as hirsutism, acne and infertility, but not with the risk for developing 
atherosclerosis as they age.  The results of this dissertation have important public health 
implications to guide researchers in developing effective ways to understand the progression of 
atherosclerosis and to assess CVD risk in women with PCOS.  This research is needed to 
provide a clear consistent message to inform researchers, clinicians and m ore importantly 
women with PCOS. 
Definitive studies on the increase in CVD events are lacking but many studies show 
women with PCOS have more CVD risk factors and subclinical atherosclerosis when compared 
to controls.  However, these studies are inconsistent so future meta-analyses could be used to 
evaluate and  summarize the current literature on CVD risk in PCOS.  This would provide 
consistent evidence on the risk of CVD in women with PCOS.   
PCOS is considered to be a state of low grade inflammation, but inflammation is not 
routinely measured in women with PCOS.  Complement protein C3 might show promise to be 
an inflammatory risk marker for CVD in women with and without PCOS.  The relation of 
circulating C3 with subclinical measures in PCOS and non -PCOS individuals suggests a 
potential mechanistic involvement of complement in the development of atherosclerosis.  
Further classification of the mechanisms of inflammation on the progression of atherosclerosis 
is needed t o identify vulnerable subgroups at risk for CVD.  Ultimately, this could lead to 
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targeted therapies to reduce inflammation and prevent the progression of atherosclerosis in high 
risk individuals.   
Flow-mediated dilation (FMD) is a widely used measure of subclinical atherosclerosis, 
but has a lot of variability that makes it hard to interpret the results from the endothelial function 
assessment.  Trajectory analysis could be used to identify subgroups with a l ow endothelial 
response and identify important factors that influence endothelial function.  Applying this analytic 
method to past and future studies of flow-mediated dilation would evaluate the utility of this 
method as it could be a more robust way to analyze endothelial data compared to current 
methods.   
In the absence of definitive studies on the risk of CVD events, PCOS is accompanied by 
CVD risk factors that place these women at an increased risk of atherosclerosis.  The results of 
this dissertation enforce recommendations for screening and monitoring CVD risk factors in 
women with PCOS as endorsed by the Androgen Excess PCOS Society, but not yet part of 
standard care.  The results also have implications that can be i ncorporated into CVD risk 
assessment and standard of care for PCOS.  This is of public health significance as young 
women with PCOS may not understand the long term effects of PCOS until they are older.  
Thus, researchers and clinicians need to send consistent messages to young women to prevent 
the development of CVD risk factors and CVD.   
6.3 FUTURE RESEARCH 
This dissertation showed that various markers of subclinical atherosclerosis could be 
used to evaluate the risk of CVD in specific populations.  It would be important to continue 
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evaluating the participants from CHARM for subclinical CVD and CVD events.  In the meantime, 
researchers can focus on understanding the mechanisms of CVD in women with PCOS.   
The association of C3 with other markers of subclinical atherosclerosis, which include 
CIMT and FMD, will be investigated in CHARM.  However, other studies are needed to confirm 
the findings that C3 may be an inflammatory risk marker for CVD in women with PCOS and 
controls.  Studies could also determine if lowering C3 has a beneficial effect on subclinical CVD. 
Endothelial function is complex and future research is needed to identify factors that 
affect the endothelial response after reactive hyperemia.  It will be important to use multiple 
methods to analyze data from the endothelial function test.  The novel trajectory analysis should 
be evaluated in different populations to assess the utility of this method.  Future studies could 
look longitudinally and see if individuals are classified into the same trajectory group over time.  
Studies could also evaluate whether changes in CVD risk factors affect group membership. 
In summary, the findings of this dissertation have implications that can be incorporated 
into CVD risk assessment and standard of care for PCOS.  Future research is needed to reduce 
inconsistencies in the literature by carefully summarizing and ev aluating the risk of CVD in 
women with PCOS.  Investigations are also needed to evaluate the utility of novel markers of 
atherosclerosis and evaluate new methods to analyze endothelial function in women with 
PCOS.  This will move the field of research forward, allowing investigators to understand the 
complexity of PCOS and the role of CVD risk factors in the progression of CVD in women with 
PCOS. 
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APPENDIX: SYSTEMATIC LITERATURE REVIEW OF FLOW-MEDIATED DILATION AMONG WOMEN WITH PCOS AND 
CONTROLS 
 
 
 
 
Table A.1 Summary of studies of flow-mediated dilation (FMD) in women with polycystic ovary syndrome and controls 
First Author, 
Year 
Control 
for Age 
and/or 
BMI 
PCOS 
Diagnostic 
Criteria 
Control 
Population Participants 
Age 
(mean±SD) 
BMI  
(mean± SD) 
Baseline 
Brachial 
Lumen 
Diameter 
(mm),  
p-value 
FMD 
Endothelial 
Function %  
(mean±SD) 
P-Value Limitations 
Mather, 
2000 Age  NIH Patients 
17 cases  32.7±1.9a 31.9±2.5a 3.06±0.13 (p=0.42) 8.7±0.8
a                                               
0.53  
Did not adjust for BMI 
(p<0.05).   Small sample 
size.  Did not mention 
hormone use.  Measured 
post-deflation diameter 
only at one minute.     
19 controls  32.4±1.4a 23.3±0.8a 2.93±0.09 9.0±0.7a  
Talbott, 
2001 Age NIH Community 
95 cases 42.6±6.0 
NA 
3.09±0.5 
(p<0.01) 7.33±5.71 
0.05 
Analysis limited to 
Caucasian women over 
30 years old.  No 
description on FMD 
protocol.  Baseline lumen 
diameter was larger 
among cases (p<0.01).  
Did not give details about 
menopausal status or 
hormone use. 
116 controls 43.7±6.2  2.88±0.37 7.15±4.17 
*Values are±SD; FMD, Flow-Mediated Dilation; NA, Not Addressed; P values are cases versus controls  
aData expressed as Standard Error (SE), bFMD at 15 seconds and 2 minutes, estimated from bar graph, cBaseline lumen diameter in cm 
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Table A.1 Continued 
First Author, 
Year 
Control 
for Age 
and/or 
BMI 
PCOS 
Diagnostic 
Criteria 
Control 
Population Participants 
Age 
(mean±SD) 
BMI  
(mean± SD) 
Baseline 
Brachial 
Lumen 
Diameter 
(mm),  
p-value 
FMD 
Endothelial 
Function %  
(mean±SD) 
P-Value Limitations 
Orio, 2004 Age and BMI NIH NA 
30 cases 22.2±2.5 22.4±2.1 3.24±0.3 (p<0.5) 14.3±1.9                                                     
<0.05 
Small sample size.  
Baseline artery diameter 
was larger among cases 
versus controls (p<0.05). 
No details on control 
selection. 
30 controls 22.6±2.3 22.1±1.8 2.96±0.4 18.1±2.0 
Tarkun, 
2004 
Age and 
BMI Rotterdam 
Doctors 
and nurses 
37 cases 23.45±4.3 23.85±3.26 3.36±0.32 (p=6.8) 9.93±2.95 0.002 Small sample size. 
25 controls 24.4±4.07 22.9±2.97 3.26±0.33 14.6±5.15 
Diamanti-
Kandarakis, 
2005, 
Clinical Trial 
BMI NIH Doctors and nurses 
20 cases 24.95±1.11a 28.37±1.59a 3.15±0.06 (p=0.48) 3.24±0.71
a                                                                             
<0.0001 
Did not adjust for age 
(p=0.046).  Small sample 
size.  Included smokers. 20 controls 26±0.90a 26.59±1.3a 3.24±0.10 8.81±1.07a 
Kravariti, 
2005 
Age and 
BMI Rotterdam NA 
62 cases 22.69±4.01 27.59±5.39 3.12±0.39 (p>0.05) 4.13±2.72  <0.001  
Small sample size.   
Measured post-deflation 
diameter only at one 
minute. No details on 
control selection. 
 23 lean  21.83±3.66  22.13±1.75  2.95±0.34 4.60±2.63 
<0.0005   
21 over-
weight 21.70±3.70  27.67±1.42  3.23±0.34 4.28±2.79 
 18 obese 24.94±4.08 34.49±2.69 3.20±0.43 3.35±2.74 
17 controls 24.77±5.66 24.96±4.26 3.09±0.47 9.09±3.99   
*Values are±SD; FMD, Flow-Mediated Dilation; NA, Not Addressed; P values are cases versus controls  
aData expressed as Standard Error (SE), bFMD at 15 seconds and 2 minutes, estimated from bar graph, cBaseline lumen diameter in cm 
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Table A.1 Continued 
First Author, 
Year 
Control 
for Age 
and/or 
BMI 
PCOS 
Diagnostic 
Criteria 
Control 
Population Participants 
Age 
(mean±SD) 
BMI  
(mean± SD) 
Baseline 
Brachial 
Lumen 
Diameter 
(mm),  
p-value 
FMD 
Endothelial 
Function %  
(mean±SD) 
P-Value Limitations 
Meyer, 2005 Age and BMI NIH Community 
100 cases 32.7±1.8a 37.3±2.43a 
NA 
9.76±0.4a 
<0.05 
Had fewer cases than 
controls.  Did not report 
baseline lumen 
diameter.   Measured 
post-deflation diameter 
only at one minute. 
20 controls 33.2±2.3a 36.7±1.28a 13.3±0.9a 
Alexandraki, 
2006 
Age and 
BMI NIH 
Doctors 
and 
medical 
students 
27 cases 25.41±0.80a 27.42±1.112a 3.05±0.06
a 
(p=0.27) 3.84±0.74
a 
<0.001 
Did not specify the 
definition of FMD.  
Studied women with 
insulin resistance and 
PCOS; excluded other 
cardiovascular risk 
factors.  Small sample 
size.  Did not mention 
smoking status. 
27 controls 27.33±0.83a  25.05±1.19a 3.17±0.09a 9.83±0.97a 
Brinkworth, 
2006 Weight Rotterdam NA 
12 cases                                                        31.9±1.8a 36.2±1.7a
NA 
6.1±1.2a                                                                                         
0.77 
Did not adjust for age 
(p=0.05).  Did not 
mention hormone use.  
Did not report baseline 
artery diameter. No 
details on control 
selection. 
10  controls  37.2±1.7a 34.4±1.5a 5.6±1.0a 
Carmina, 
2006 
Age and  
weight NIH NA 
50 cases  25.2±1a  28.7±0.8a 
NA 
15± 0.6a                                                               
<0.05 
Did not take into 
account hormone use or 
smoking status.  Did not 
report baseline artery 
diameter. No details on 
control selection. 
50 controls  25.1±0.7a 28.5±0.5a 18.2± 0.8a 
*Values are±SD; FMD, Flow-Mediated Dilation; NA, Not Addressed; P values are cases versus controls  
aData expressed as Standard Error (SE), bFMD at 15 seconds and 2 minutes, estimated from bar graph, cBaseline lumen diameter in cm 
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Table A.1 Continued 
First Author, 
Year 
Control 
for Age 
and/or 
BMI 
PCOS 
Diagnostic 
Criteria 
Control 
Population Participants 
Age 
(mean±SD) 
BMI  
(mean± SD) 
Baseline 
Brachial 
Lumen 
Diameter 
(mm),  
p-value 
FMD 
Endothelial 
Function %  
(mean±SD) 
P-Value Limitations 
Diamanti-
Kandarakis, 
2006 
Age and 
BMI NIH 
Doctors 
and 
medical 
students 
25 cases 25.64±0.86a 29.08±1.43a 3.11±0.29
a 
(p=0.24) 3.47±0.75
a 
<0.001 Small sample size. 
25 controls 27.52±1.02a 26.22±1.16a 3.25±0.47a 9.26±0.98a 
Sorensen, 
2006 
 
 
 
 
 
 
 
 
Age and 
BMI 
NIH & 
Rotterdam NA 
14 cases 33.4±3.56 25.1±3.75 
NA 
2.49±4.7 
0.0003 
Small sample size.  Did 
not report baseline 
artery diameter.   
Measured post-deflation 
diameter only at one 
minute. No details on 
control selection. 
13 controls 32.7±5.74 24.7±3.90 11.5±5.7 
Beckman, 
2007 
Age and 
BMI NIH 
News-
paper ads 
and 
diabetes 
center 
10 cases 31±6 30±5 
NA 
9.9±0.7a >0.05 
Small sample size.  Did 
not mention hormone 
use.  Did not report 
baseline artery 
diameter.   Measured 
post-deflation diameter 
only at one minute. 
6 lipo-
dystrophic 
women 
47±13 27±3 7.7±1.2a >0.05 
12 type 2 
diabetic 
women 
56±14 31±7 3.4±1.3a 0.02 
19 controls 41±11 26±7 7.3±1.1a   
*Values are±SD; FMD, Flow-Mediated Dilation; NA, Not Addressed; P values are cases versus controls  
aData expressed as Standard Error (SE), bFMD at 15 seconds and 2 minutes, estimated from bar graph, cBaseline lumen diameter in cm 
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Table A.1 Continued 
First Author, 
Year 
Control 
for Age 
and/or 
BMI 
PCOS 
Diagnostic 
Criteria 
Control 
Population Participants 
Age 
(mean±SD) 
BMI  
(mean± SD) 
Baseline 
Brachial 
Lumen 
Diameter 
(mm),  
p-value 
FMD 
Endothelial 
Function %  
(mean±SD) 
P-Value Limitations 
Lowenstein, 
2007, 
Clinical Trial 
 BMI  Rotterdam 
Medical 
staff and 
colleagues 
31 cases 24.3±6.8 24.2±5.3 
NA 
1.48±0.32                                                                                                                                           
0.001 
Did not adjust for age 
(p=0.001).  Did not 
measure insulin 
resistance.  Used the 
Endo-PAT to measure 
FMD.  Small sample 
size.  Did not mention 
hormone use.  Did not 
report baseline artery 
diameter. 
 33 controls 33.4±11 22.4±4.6 2.00±0.51  
Battaglia, 
2008 
Age and 
BMI Rotterdam NA 
28 cases 25.2±4.0 25.2±4.5 
NA 
(p>0.05) 
6 (15 secs), 
3 (2 min)b <0.05 
Listed baseline artery 
diameter and FMD in a 
bar graph and not a 
table with standard 
deviations.  Small 
sample size. No details 
on control selection. 
17 PCO  24.9±3.6 26.6±6.1 
10  
(15 secs),  
4.5 (2 min)b 
  
15 controls 26.5±4.4 25.9±5.1 
11.5  
(15 secs),       
10.5  
(2 min)b 
  
Cascella, 
2008 
Age and 
BMI Rotterdam NA 
200 cases 24.6±3.2  28.5±2.8 
NA 
13.7±2.3 
<0.001 
Did not assess smoking 
status.  Did not report 
baseline artery 
diameter. No details on 
control selection. 
100 controls 24.0±2.8 28.8±2.7 17.8±2.2 
*Values are±SD; FMD, Flow-Mediated Dilation; NA, Not Addressed; P values are cases versus controls  
aData expressed as Standard Error (SE), bFMD at 15 seconds and 2 minutes, estimated from bar graph, cBaseline lumen diameter in cm 
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Table A.1 Continued 
First Author, 
Year 
Control 
for Age 
and/or 
BMI 
PCOS 
Diagnostic 
Criteria 
Control 
Population Participants 
Age 
(mean±SD) 
BMI  
(mean± SD) 
Baseline 
Brachial 
Lumen 
Diameter 
(mm),  
p-value 
FMD 
Endothelial 
Function %  
(mean±SD) 
P-Value Limitations 
Arikan, 2009 Age and BMI Rotterdam 
Staff and 
medical 
students 
39 cases 22.82±5.53 21.48±6.50 3.54±0.37 (p>0.05) 24.88±9.63 >0.05 
Did not assess hormone 
use.  Small sample size.    
 30 controls 24.64±4.22 20.90±6.04 3.81±0.66 22.35±9.40 
Luque-
Ranurez, 
2009 
Age and 
BMI Rotterdam NA 
40 cases 26±6 29.4±6.3       
Small sample sizes.  
Separated data by 
obesity status.  Included 
smokers. No details on 
control selection. 
 
Obese 
(16) 26±7 35.8±3.9 
0.34±0.06c 
(p=0.065) 10.3±9.6   
 
non-
0bese 
(24) 
23±5 25.1±3.3 0.35±0.04c 7.1±10.7 0.229 
20 controls 27±7 28.2±6.9     
   
Obese 
(8) 29±6 35.5±3.2 0.39±0.04
c  5.3±5.4 
  
Non-
obese 
(12) 
26±8 23.3±3.2 0.36±0.04c 5.6±9.3 
Soares G, 
2009 
Age and 
BMI Rotterdam 
Basic 
health clinic 
40 cases 24.5±3.8 22.7±3.3 3.00±0.35 (p=0.14) 8.1±3.6 0.80 
Measured post-deflation 
diameter only at one 
minute. 50 controls 24.5±5.1 23.1±3.2 3.10±0.34 8.36±3.5 
*Values are±SD; FMD, Flow-Mediated Dilation; NA, Not Addressed; P values are cases versus controls  
aData expressed as Standard Error (SE), bFMD at 15 seconds and 2 minutes, estimated from bar graph, cBaseline lumen diameter in cm 
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Systematic Literature Review Methods for Flow-Mediated Dilation in Women with Polycystic Ovary 
Syndrome and Controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1 Diagram of search strategy used to identify articles for review of flow-mediated dilation (FMD) 
in women with Polycystic Ovary Syndrome (PCOS)* 
 
*Inclusion criteria: primary article with a study population with women with PCOS and controls, and had a 
measure of FMD 
 Note: A PubMed search (Brachial Artery/physiopathology"[MeSH Terms] AND ("Polycystic Ovary 
Syndrome"[MAJR]) did not identify new papers.  
Search of EMBASE 
1980- January 2009  
('brachial artery'/exp OR 'brachial 
artery') AND ('ovary polycystic 
disease'/exp OR 'ovary polycystic 
disease') AND [humans]/lim AND 
[1980-2009]/py       
-searched as free text as well 
Excluded 6 articles: 
1 review article, 6 articles 
were randomized clinical 
trials and/or no controls  
 
24 Articles 
Evaluate Abstracts using Inclusion 
Criteria* 
 
17 Articles 
Total articles included in  
Feb 2010 review  
 
20 Articles 
 
Included 1 article from a book and 2 
articles sent via PubMed update’s e-mail 
service  
 
3 Articles + 
18 Articles 
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